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古今之成大事业、大学问者，必经过三种之境界：  
 
“昨夜西风凋碧树，独上高楼，望尽天涯路。” 此第一境也。  
“衣带渐宽终不悔，为伊消得人憔悴。” 此第二境也。  
“众里寻他千百度，蓦然回首，那人却在，灯火阑珊处。”此第三境也。 
 
——王国维《人间词话》 
 
Throughout the ages of all those who have been highly successful in great ventures and in the pursuit 
of learning must of necessity have (successively) experienced three kinds of “ching-chieh”. 
“Last night the west wind shrivelled the green-clad trees, 
    Alone I climb the high tower 
      To gaze my fill along the road to the horizon.” 
expresses the first state of (ching) 
“My clothes grow daily more loose, yet care I not. 
    For you am I thus wasting away in sorrow and pain.” 
expresses the second state. 
“I sought her in the crowd a hundred, a thousand times. 
    Suddenly with a turn of the head (I saw her), 
      That one there where the lamplight was fading.” 
expresses the third state. 
——„Jen-chien Tz'u-hua“ by Wang Kuo-wei  
translated by Adele Austin Rickett 
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1 Introduction 
1.1 Nucleic acid therapy: opportunities and challenges 
Since the first evidence that genetic information is carried by deoxyribonucleic acid (DNA) 
was presented in 1944,[1] the description of double helix structure of DNA by Watson and 
Crick,[2] as well as the illustration of central dogma,[3] the related molecular biology has 
been intensively investigated, changing and enriching our understanding about basis of 
life. The completion of Human Genome Project and latter continuous efforts to decrypt 
human genome provide us enormous information about genes, and also help us to identify 
disease related genes.[4] Nowadays, many diseases are known to be caused by genetic 
defects, such as inherited single gene disorders (like Huntington’s chorea[5], or cystic 
fibrosis[6]), or acquired disorders such as in cancer. Gene therapy provides an option for 
the treatment of these genetic disorders and other severe diseases by genetically 
modification of the target cells.[7] Although the first documented heritable gene transfer 
was performed with mammalian cells over 50 years ago,[8] the first officially approved 
gene transfer into humans was conducted in 1989[9]. Currently, there are over 2000 
approved clinical trials worldwide completed or still ongoing.[10] After decades of 
development, China first approved a gene therapy product Gendicine for the treatment of 
head- and neck squamous cell carcinoma in 2003,[11] and finally in 2012, Glybera 
became the first gene therapy product approved by European Medicines Agency.[12] 
The initial approach of gene therapy was carried out by substituting defective genes with 
therapeutic DNA delivered into the nucleus.[7] The first gene therapy human clinical trial 
approved by the US FDA for the treatment of severe combined immune deficiency (SCID) 
was proceeded under this strategy.[13] With increasing knowledge of the biological role 
of RNA, in addition to the application of therapeutic DNA, the delivery of RNA has also 
been widely involved. In contrast to the delivery of DNA which require intracellular location 
into nucleus, direct transfer of messenger RNA (mRNA) into cytosol provides another 
approach to code protein products. Additionally, the option of suppressing pathogenic 
gene expression have been established. Antisense oligonucleotides, which specific 
complementary bind to the target mRNA, suppress the translation of target mRNA by 
either steric-blocking or mRNA degrading. Furthermore, the discovery of RNA 
interference (RNAi) provide as a novel approach to suppress a specific gene. Based on 
the classic gene silencing strategy of using single stranded oligonucleotides, double-
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stranded RNA (dsRNA) with over 30 base pairs was first discovered to be able to mediate 
suppression of a specific gene in C. elegans.[14] The latter attempt successfully achieved 
effective silencing of target genes in mammalian cells via application of the shorter small 
interfering RNA (siRNA) without immune responses.[15] RNAi based therapy offers as a 
remarkable approach for sequence-specific suppression of gene expression. Other 
nucleic acid types, such as micro RNA (miRNA), polyinosinic-polycytidylic acid (poly(I:C)), 
splice-switching oligonucleotides (SSOs), as well as aptamers have also been extensively 
investigated as tools for gene therapy. 
Despite these dramatic achievements in seeking novel strategies for gene therapy, one 
inherent week point is the biological instability of naked therapeutic nucleic acid. A variety 
of chemical nucleic acid modifications focusing on the improvement of stability, 
therapeutic potency, as well as reduced immunogenicity, have been developed. 
Commonly chemical modifications include 2’-O-methyl or 2’-fluoro RNA, 2’-O, 4’-C-
methylene bridges (locked nucleic acid, LNA), phosphorothioate or phosphorodiamidate 
morpholino oligomers (PMOs) and peptide nucleic acid (PNA).  
Although the variety of different nucleic acid forms provides us a wide range of therapeutic 
options, the efficient targeted delivery of therapeutic nucleic acids into the affected patient 
cells remains the main challenge. Therefore, the availability of an efficient and safe 
delivery vehicle is a crucial factor for success. 
1.2 Conquering barriers: non-viral nucleic acid carriers 
Despite remarkable progress in gene therapy have been made over the past few decades, 
the development of appropriate therapeutic nucleic acid delivery systems with high 
efficiency and biocompatibility remains a challenge to be conquered. Learning from nature, 
viruses provide us excellent examples for transfer of nucleic acid into targeted cells. 
Nowadays, the majority of gene therapy studies are using recombinant viral vectors like 
adeno-associated vectors, retroviral vectors and lentiviral vectors. Originated from natural 
virus, these viral vectors obtained by replacing most of the virus genome with therapeutic 
gene exhibit high transfection efficiency. However, some disadvantages of viral carriers 
such as immunogenicity, limited loading capacity, risk of insertional mutagenesis, and 
difficulties in optimization of production and upscale have hindered them from being the 
ideal commonly applicable nucleic acid delivery carrier. A subclass of non-viral carriers, 
known as synthetic “artificial viruses” provide an option for the development of nucleic 
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acid delivery systems with high efficiency and low toxicity. Currently, their transfection 
efficiency is relatively low as compared to the viral vectors. However, non-viral carriers 
possess the advantages of low immunogenicity, high biocompatibility, possibilities for 
further optimization with multi-functional groups and good potential for scale-up 
manufacturing. 
Since a successful nucleic acid based therapy requires successful delivery of the 
therapeutic nucleic acid into the target cell. The nucleic acid delivery systems need to 
protect the payload from various extracellular and intracellular barriers (Figure 1.1), and 
reach the final targeting site. Generally, an ideal carrier needs to 1) compact the cargo 
into nanoparticles with suitable particle size to protect from nucleases and clearance from 
kidney; 2) bear surface shielding domains to limit the interaction with serum proteins and 
mediate effective and selective cellular uptake; 3) efficiently escape from intracellular 
endo-lysosomal pathway; and 4) transfer the cargo to the target intracellular site.  
 
Figure 1.1 Systemic nucleic acid delivery pathway. 
 
1.2.1 Nucleic acid complexation 
As nucleic acids are enzymatically degradable in the blood and tissues, carriers need to 
compact them into stable complexes, to protect them from being degraded by nucleases 
and cleared from the blood stream. Because of the negatively charged nature of nucleic 
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acid, most non-viral vectors, like cationic lipid, polyethyleneimine (PEI) and dendrimer, 
facilitate the complexation with the cargo through electrostatic interaction. The stability of 
the formed complexes is another critical issue to be mastered. Besides manipulating the 
charge density of the carrier, enhanced complex stability could be achieved via the 
introduction of crosslinking domains and hydrophobic domains. For systemic delivery of 
nucleic acid, the particle size of complexes also plays a crucial role. While particles with 
smaller size are rapidly cleared form the kidney, complexes with an appropriate size lead 
to an extended circulation time, which is beneficial for an improved bio distribution and 
pharmacokinetic profile. 
1.2.2 Targeted intracellular accumulation 
Many non-viral vectors form nucleic acid complexes with a net positive charge, increase 
the unspecific interaction with undesired cell membrane and proteins, leading to a 
reduced delivery of the payload into the targeted cells. The incorporation of shielding 
domains might solve this problem. Hydrophilic polymers such as polyethylene glycol 
(PEG), have been used to coat the surface of polyplexes, resulted in reduced unspecific 
interactions with blood component during circulation. [16, 17] Other polymers, like poly-
N-(2-hydroxypropyl)methacrylamide (pHPMA) and hydroxyl ethyl dextran (HES) [18] have 
also been used for this purpose.  
To enable subsequent accumulation of the therapeutic payload at the target tissue, 
different passive and active targeting attempts have been involved. In the case of tumor 
directed nucleic acid delivery, accumulation at the target tumor tissue has been obtained 
based on the enhanced permeability and retention effect (EPR), because of the more 
leaking vascular endothelium in tumors[19]. Here again the influence of particle size on 
the delivery pathway is illustrated. To facilitate intracellular entry, polyplexes must initially 
associate with the cell surface, either through electrostatic interactions, physical 
concentration via adsorption, or by ligand–receptor mediated pathways. By the use of 
specific targeting ligands, it is possible to allow binding to specifically expressing or over 
expressing receptors on the target cell surface.[20] Enhanced specific cellular uptake has 
been achieved by the use of transferrin, folate, RGD, GE11, cMet and other targeting 
ligands. The use of active targeting ligand also help to combat with the PEG-dilemma in 
the case of PEGylated formulations. After successful cellular uptake, the nucleic acid 
complexes usually reside in internal vesicles (endolysosomes) facing next challenges. 
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1.2.3 Endosomal escape 
The next delivery task is the escape of polyplexes from the degradative endolysosomal 
pathway, to prevent lysosomal degradation of the payload and deliver it safely to their 
targeting site into either the nucleus or cytosol. This can be achieved through several 
strategies. Similar to PEI, several carriers with intrinsic pH-specific buffering capacity 
could facilitate endosomal escape through the so-called proton sponge effect.[21] Like for 
several lipid-based systems, this escape from the endo-lysosomal pathway can also be 
promoted by destabilization of the endosomal membrane. Additionally, chemical motifs 
such as histidine [22, 23] and imidazole groups [24] which enhance the buffer capacity at 
the endosomal pH, can be incorporated to achieve successful endosomal escape.  
As an alternative to the proton sponge mechanism, endosomal escape was mediated by 
fusogenic peptides, including amphipathic sequences and/or peptides with high content 
of basic amino acids[25], such as Tat[26], melittin[27, 28], influenza virus-derived INF 
peptides[29, 30], KALA[31] and others.[32, 33] This kind of peptides can interact with the 
endosomal lipid membrane and lead to their disruption.[25] Several fusogenic peptides 
were used in combination with cationic peptides, polymers, or other gene delivery carriers. 
1.2.4 Intracellular trafficking and cargo release 
After successfully escape from endosome, further transportation to the final target site of 
action is dependent on the type of nucleic acid. While siRNA and miRNA only need to 
locate in the cytosol, pDNA has to be urther transported all the way into the nucleus. This 
has been demonstrated to preferentially happen during the cell division process when the 
nuclear envelope dissolves.[34] Attempts have been made through conjugating short 
nuclear localization signals (NLS) peptide to DNA for a targeted active transport through 
the nuclear pore complex.[35-37] It has also been suggested that some cationic polymers 
may have a nuclear-localizing effect because of their positive charge. While the transport 
of polyplexes into the nucleus is still not clearly understood and requires further 
optimization at several stages,[38] studies have shown that it seems to be advantageous 
to use pDNA polyplexes for nuclear transfer.[39, 40] 
Another critical issue is the cargo release. As we mentioned in the nucleic acid compaction, 
the complexes need to be stable enough to help them be able to transport to the action 
site. However, at the target site, the high stability of the complexes might hinder the 
release of the cargo, thus lead to reduced transfection efficiency. In this case, the formed 
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complexes need to find a balance between a sufficient extracellular stability and fast cargo 
release at the final stage. The bio-inspired redox sensitive strategy which commonly 
facilitated as the incorporation of bioreducible disulfide linkage presents a successful 
example.[41] Relatively stable complexes was formed via the formation of disulfide 
linkage in the extracellular conditions, while in the final cytosol, with the help of 
approximately 100 to 1000 fold glutathione, the fast reduction also contribute to the fast 
release of the cargo.[42] This strategy also shows the benefits for the biocompatibility of 
the delivery system. 
1.3 Sequence-defined materials for nucleic acid delivery 
Within the class of polymeric delivery systems, polyethylenimine (PEI) has been the most 
investigated cationic carrier for pDNA delivery, it presents a gold standard for pDNA 
transfection. PEI has a very high density of amino groups, beneficial for both stable pDNA 
complex (‘polyplex’) formation, and also possesses buffering capacity to mediate 
endosome escape of polyplexes into the cytosol.[21, 43] Many efforts have been 
undertaken to optimize PEI based delivery systems, introducing biodegradable linkages, 
and/or attaching targeting and shielding functions.[44-46] However, the polydispersity and 
heterogeneities of such multifunctional structures presents a big problem for further 
development. Specific modifications in defined numbers at different polymer sites are 
difficult to achieve. Such a heterogeneous nature of PEI and also other related polymeric 
materials such as poly(L-lysine) is hardly compatible for reproducible manufacturing of 
components as needed for clinical studies.  
This fundamental drawback has been calling for more defined polymeric materials for 
gene delivery.[47] A precise chemistry is not only useful for the site-specific modification 
that is required to develop a defined multi-functional vector, but also important for 
obtaining the structure-activity relationships needed for further optimization. Thus, several 
synthetic strategies have been utilized to obtain better defined cationic polymeric 
materials. These include improved polymerization chemistries such as controlled radical 
polymerization, providing a narrow polymer size-distribution. Defined block copolymers, 
optionally also with defined ligation sites, can be obtained.[48-50] Alternatively, step-wise 
synthesis of precise dendrimers[51] has been utilized to obtain defined cationic polymeric 
materials. Recently also solid-phase assisted synthesis of peptides and polymers has 
been introduced.[52] These sequence-defined carriers can be applied for nucleic acid 
delivery. 
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1.3.1 Dendrimers 
Dendrimers are globular macromolecules with well-defined, highly branched three-
dimensional architecture, generated by precise step-wise introduction of branching points 
onto a core molecule.[53] With monodispersity and high density of multivalent functional 
surface groups, they exhibit attractive properties as precise nucleic acid delivery 
platform.[54]  
Polyamidoamine (PAMAM) dendrimers (Figure 1.2A) [51]have high density of amines 
which can be partially protonated at physiological pH to complex with nucleic acid, while 
the large numbers of secondary and tertiary amines at the interior act as “proton sponge” 
to mediate efficient endosome escape.[55] With pioneering studies proving that PAMAM 
can mediate high transfection efficiency, [56, 57] considerable optimization in the aspects 
of biocompatibility, polyplex formation, endosomal escape, and targeted delivery has 
been made. [57] With reduced surface charge density including partial acetylation or 
PEGylation,a reduced inherent cytotoxicity was obtained.[58] Via introducing L-lysines 
and L-arginines as surface modification, improved polyplex formation as well as cellular 
interaction was demonstrated. [59] Enhanced endosomal escape with the integrate of 
histidine residues lead to an effective delivery of pDNA.[60] Many other efforts 
manipulating the dendrimer surface charge and hydrophobicity, including the introduction 
of hydrophobic phenylalanine,[61] leucine,[61] or alkyl lipid[62] residues all showed 
encouraging results. Recently, a fluorination approach of PAMAM dendrimers via reacting 
with perfluoro acid anhydrides formed fluorinated dendrimers with low toxicity and 
significant improved transfection efficacy in several cell lines at extremely low N/P ratios, 
which is comparable or superior to commercial agents Lipofectamine 2000 and 
SuperFect.[63] Another important topic, the targeted delivery of nucleic acid, has also 
been introduced into PAMAM dendrimers. Targeting moieties such as biotin,[64] 
transferrin,[65] folic acid,[66] lactose,[67] and peptides[68, 69] were investigated. In 
several cases successful targeted in vivo gene transfer was reported.  
Poly(propylenimine) (PPI) dendrimers (Figure 1.2B),[53] just like PAMAM, can compact 
nucleic acid via electrostatic interactions with the positively charged protonated amino 
groups, while the residual amines provide endosomal buffering.[70] Researchers have 
utilized amino acids like arginine[71], galactose[72], transferrin[73], oligoethylenimine[74] 
and other modules to modify PPI dendrimers, resulting in improved transfection efficiency 
with reduced cytotoxicity, and optionally also receptor targeting. For example, transferrin-
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conjugated PPI G3 was used in pDNA polyplexes for systemic delivery in A431 tumor-
bearing mice. Gene expression was predominantly observed in the tumor tissue, with 
long-term therapeutic antitumoral effects was exhibited upon a therapeutic tumor 
necrosis-α (TNF-α) expressing pDNA treatment.[73] 
 
Figure 1.2 Chemical structure of three typical dendrimers. A) PAMAM (G1) dendrimer. B) PPI dendrimer 
(DAB8). C) Poly(L-lysine) dendrimer (G2). 
Poly(L-lysine) dendrimers (DPL, Figure 1.2C) [75] also show their potential as effective 
nucleic acid carriers. Similarly, variations of the terminal residue with arginines 
demonstrated as an efficient way to enhance gene transfer.[76] With regard to optimize 
the synthesis of higher generation DPL, Luo et al.[77] utilized a click chemistry strategy 
and obtained arginine grafted dendrimers with higher transfection efficiency than 
branched PEI (25 kDa). DPLs have also been successfully used for receptor-targeted 
gene transfer to the brain.[78-80] The peptidic ligands T7 targeting the transferrin 
receptor,[78] angiopep-2 targeting the LDL receptor-related protein LRP1,[79] or a 
bacterial protein derived peptide targeting the laminin receptor,[80] have been used as 
PEG-DPL conjugates for pDNA polyplex formation. Successful in vivo gene delivery into 
brain and brain tumors was reported. 
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1.3.2 Peptide based carriers 
Peptide based nucleic acid carriers have several favorable platform characteristics. They 
can condense nucleic acid through electrostatic interaction with the help of the natural 
amino acids lysine, arginine, or ornithine providing positive charges,[81] and also achieve 
many other transfer functions such as endosomal escape, bioreversible polyplex 
stabilization, or receptor-targeted delivery. Amongst the key advantages of peptide 
carriers are the sequence-defined structure and the monodispersity obtained by solid-
phase assisted peptide synthesis (SPPS), which are beneficial for establishing precise 
structure-activity relationship studies.  
Oligolysine peptides consisting defined length of lysine provide an alternative to the 
heterogeneous poly-(L-lysine). The precise structure also makes it possible to perform 
site-specific modification. Studies have shown that oligolysine containing 13 or more 
lysine monomers are able to compact pDNA,[82] and a peptide containing 18 lysines is 
able to from stable polyplexes with pDNA protecting them from degradation.[83] Coupling 
a trimeric galactoside-containing ligand to an oligolysine of 19 monomers resulted in an 
asialoglycoprotein receptor targeted carrier which mediated efficient gene transfer in 
HepG2 cells in the presence of endosomotropic chloroquine.[84][94] A defined Lys30 
terminally modified with PEG was used in pDNA polyplexes in human clinical studies for 
expressing the CFTR gene in the airway epithelium of cystic fibrosis patients.[85]  
To further improve the stability of DNA complexes, cross-linking strategies have been 
developed. Cysteine has been introduced into the peptide sequence to form bioreversible 
disulfide bonds through oxidation.[86] McKenzie et al. investigated modifications of Trp-
Lys20 peptide by substitution one to four of the lysines with cysteines. The peptide with 
two terminal cysteines showed the highest transfection efficiency.[87] Similar transfection 
efficiency was achieved with shortened lysine chains consisting of only four lysines and 
two terminal cysteines.[87] Read et al. prepared a bioreducible polylysine analog by 
oxidative polymerization of Cys-Lys10-Cys (CK10C). In the presence of either chloroquine 
of the cationic lipid DOTAP efficient pDNA gene transfer was observed which was far 
more effective than analogous studies with a nonreducible standard poly(L)lysine.[88] 
In order to achieve more efficient endosomal escape, histidine-rich or fusogenic peptide 
domains were incorporated. The histidine-containing oligolysine sequence CHK6HC was 
found to possess a 10-fold higher transfection efficiency than the control peptide without 
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histidine.[87] Analogously, bioreducible polymers based on oxidation of CH3K3H3C and 
CH6K3H6C demonstrated improved activity over C-K10-C based polymers.[89] The group 
of Mixson developed a series of branched oligopeptides containing nucleic acid binding 
lysines and endosomal-buffering histidines. They discovered that different peptide 
sequences were needed for optimized pDNA and for siRNA delivery.[90, 91] Lu and 
colleagues used solid-phase assisted peptide synthesis for inserting defined oligoamines 
such as triethylene tetramine into histidine and terminal disulfide-forming cysteine 
containing peptides, which were subsequently oxidized into polymers used for nucleic 
acid delivery.[92] 
1.3.3 Sequence-defined oligoaminoamide carriers 
Solid phase synthesis (SPS), introduced by Merrifield in 1963, are widely used to 
synthesize sequence defined oligopeptide. This method also provides an option to 
introduce artificial building blocks with proper functional groups to the SPS process, and 
enables a stepwise assemble of sequence defined polymeric product. Hartmann et al. 
successfully modified the classical approach, and obtained sequence-defined linear 
poly(amidoamines) (PAA).[52, 93-98] Optionally, disulfide moiety [93], PEG [52, 93, 94], 
novel chiral building blocks [97], as well as building blocks allowing asymmetrical 
branching [98] have been introduced into the syntheses of multifunctional PAAs. 
Schaffert et al. introduced a set of novel artificial amino acids comprising repeats of the 
1,2-diaminoethane motif derived from the classic gene carrier polyethylenimine (PEI). 
Such artificial oligoamino acids (Figure 1.3 A), like glutaryl-triethylene tetramine (Gtt), 
glutaryl-tetraethylene pentamine (Gtp), succinoyl-tetraethylene pentamine (Stp) [99] and 
succinoyl-pentaethylene hexamine (Sph) [100], are fully compatible with the standard 
Fmoc-based SPS. In combination with natural α-amino acids, they were applied in SPS 
to generate sequence-defined cationic oligomers for nucleic acid delivery, provide 
excellent nucleic acid binding ability, endosomal buffering capacity, and an option of site-
specific positioning of multiple functionalities.[101] Continuous efforts have been taken to 
optimize this type of cationic oligomers for nucleic acid delivery, resulted in a library of 
over 1000 sequence defined oligomers as potential nucleic acid carriers (Figure 1.3 B).  
Starting from the basic linear oligomers, i-shape, U-shape as well as T-shape olgiomers 
have been synthesized.[101] Additionally, three arm[101, 102], four arm[100], and even 
five arm[100] structure could be obtained. Scholz et al.[103] developed a library of comb-
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like oligomers using oligolysine as the backbone which was modified with one out of four 
different artificial oligoamino acids at the lysine ε-amino groups (for example see oligomer 
552 in Figure 1.3B). Results showed clear differences between the comb and linear 
oligomers as pDNA carriers, and comb-like Stp containing structures was found an overall 
advantage compared to the linear oligomers in the aspect of buffering capacity, cellular 
uptake, and transfection efficiency. 
Figure 1.3 Sequence-defined oligomers. A) Artificial oligoamino acid building blocks. B) Exemplary 
oligomer structures (N-terminus left, C-terminus right). Linear structures (such as 23), three-arm (386), 
four-arm structures (497), lipid containing oligomers (80, 230, 278), comb structures (552), tyrosine-
containing structures (454), and receptor-targeted and histidine-containing structures (620) were designed. 
C, cysteine; K, lysine; H, histidine; A, alanine; Y, tyrosine; LinA, linolic acid; OleicA, oleic acid; FolA, folic 
acid; PEG24, monodisperse polyethylene glycol consisting of 24 ethylene glycol units. 
 
The integration of small chemical motifs into the oligomers enables generation of 
multifunctional carriers for nucleic acid delivery. In this case, fatty acid have been 
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incorporated for hydrophobic stabilization of polyplexes, as well as manipulating 
endosomal escape.[104] Another stabilizing modification was achieved by the integration 
of tyrosine trimers (see Figure 1.3B, oligomer 454). A combination of terminal 
oligotyrosines and cysteines was favorable for forming stable polyplexes, and exhibited 
an enhanced transfection efficiency in most cases.[105] Alternatively, twin disulfide 
forming units have also been investigated for the redox sensitive polyplexes stabilization 
and dissociation.[106] Lächelt et al. focused on the fine-tuning of endosomal buffering 
capacity with a library of sequence-defined oligomers containing different building blocks 
with and without histidine. The result reveal that building blocks with even numbers of 
protonatable amine groups exhibited higher total endosomal buffer capacity than those 
with odd numbers. In addition, the introduction of buffering histidines increased the buffer 
capacity, and resulted in a further improvement of gene transfer efficiency both in vitro 
and in vivo.[23] 
This SPS-based oligomer platform also enable assemble of oligomers for receptor-
targeted delivery. Martin et al. [107] first utilized peptide B6 and c(RGDfK) as targeting 
ligands, for binding the transferrin receptor or αvβ3 integrin, respectively. Effective specific 
gene transfection could be achieved only in combination with endosomolytic agent 
chloroquine. The introduction of buffering histidines into the backbone of the targeting 
oligomers (see for example Figure 1.3B, oligomer 620), resulted a targeted and high 
transfection efficiency in the absence of chloroquine.[23] Unlike the mentioned stepwise 
SPS strategy, native chemical ligation chemistry provides an interesting option for a site-
specific converting non-targeted oligomers into folate targeting PEGylated oligomers.[108] 
The application of other targeting ligands like a cMet binding peptide [109], GE11 [110], 
Angiopep-2 [111], transferrin [112] all provided interesting results essential for future 
optimization. Recent progress in the co-formulation of two different oligomers achieved in 
vitro dual targeting effects [110], efficient in vivo gene expression in combination of cMet 
targeted oligomer with 3-arm histidine integrated oligomer[109], and remarkably brain 
targeted siRNA delivery with Angiopep-2 bearing PEGylated 2-arm oligomer with lipo-
oligomer 49 [111]. 
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1.4 Aims of the thesis 
The current thesis focuses on the combinatorial optimization of oligomers with precise 
molecular structure and site-specific modification in the development of multifunctional 
carriers for nucleic acid delivery.  
The first aim of the thesis was combinatorial optimization of sequence-defined 
oligo(ethanamino)amides for folate receptor-targeted pDNA and siRNA delivery. For this 
purpose, a library of sequence-defined oligomers comprising the artificial polyamino acids 
Stp and Sph for nucleic acid complexation, monodisperse polyethylene glycol (PEG) for 
surface shielding, and folic acid for receptor-specific cellular uptake, in combination of 
alternating different topologies of branched cationic oligomers, optionally containing 
endosomal buffering histidines and/or hydrophobic tyrosine trimers had to be designed 
and synthesized in order to systematically evaluate their properties in pDNA and siRNA 
delivery. The ligand-dependency of the nucleic acid transfer by comparing with analogous 
folate-free oligomers had to be included. The findings of this study should provide 
identified different beneficial modules for the delivery of pDNA and siRNA and structure 
activity relationships for further optimization of targeted oligomers. 
The second aim was to provide an alternative efficient option to obtain a multifunctional 
targeting carrier by combination of two different oligomers for the formulation of 
therapeutic siRNA polyplexes. For this purpose, siRNA polyplexes in combination with 
folate-PEG-containing oligomers (for FR targeting and shielding of surface charges) and 
a 3-arm oligomer (for optimizing particle size and stability) at various molar ratios had to 
be formulated to optimize the physicochemical properties of polyplexes. Therefore an 
easy conjugation strategy had to be developed for uni-directional fast coupling between 
the two types of oligomer. These targeted combinatorial polyplexes (TCP) had to be 
systematically evaluated in order to find an optimal siRNA polyplex formulation. 
The final aim was to investigate branched fatty acid containing oligomers for nucleic acid 
delivery. For this purpose, a library of fatty acid containing oligomers with different cationic 
branches had to be synthesized in order to evaluate their potential as nucleic acid carriers. 
The influence of different cationic branches on the delivery of pDNA and siRNA should be 
identified. 
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2 Materials and Methods 
2.1 Chemicals and reagents 
2-Chlorotrityl chloride resin, all Fmoc or Boc protected α-amino acids, peptide grade 
dimethylformamide (DMF), N,N-diisopropylethylamine (DIPEA), piperidine and 
trifluoroacetic acid (TFA) were purchased from Iris Biotech (Marktredwitz, Germany). 
Benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (Pybop) and 
syringe microreactors were obtained from Multisyntech GmbH (Witten, Germany). 1-
Hydroxy-benzotriazole (HOBt), triisopropylsilane (TIS), tris(2-carboxyethyl)phosphine 
(TCEP), 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB), 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU), 3,6-dioxa-1,8-octanedithiol (DODT), dimethylsulfoxide (DMSO) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from from 
Sigma-Aldrich (Munich, Germany), hydrazine from Merck (Darmstadt, Germany), and 25% 
ammonia solution from Carl Roth (Karlsruhe, Germany). N10-(trifluoroacetyl) pteroic acid 
was obtained from Niels Clauson-Kaas A/S (Farum, Denmark), and Fmoc-N-amido-
dPEG24-acid from Quanta Biodesign (Powell, USA). All other solvents and small 
molecular reagents were obtained in high quality (analytical or HPLC grade). Acetonitrile 
(ACN, HPLC grade) was obtained from VWR (Darmstadt, Germany), deuterium oxide 
(D2O) from Euriso-Top (Saint-Aubin Cedex, France), dichloromethane (DCM) from Bernd 
Kraft (Duisburg, Germany), n-hexane and methyl-tert-butyl ether (MTBE) from Brenntag 
(Mülheim/Ruhr, Germany). Ninhydrin, phenol, potassium cyanide (KCN), sodium 
hydroxide (NaOH), Hydrochloric acid solution (HCl, 1M) were purchased from Sigma-
Aldrich (Munich, Germany). Water was used as purified, deionized water. Cell culture 
media, fetal bovine serum (FBS) and antibiotics were purchased from Life Technologies 
(Darmstadt, Germany), glucose from Merck (Darmstadt, Germany), and HEPES from 
Biomol GmbH (Hamburg, Germany). Luciferase cell culture lysis buffer and D-luciferin 
sodium were obtained from Promega (Mannheim, Germany). pCMVLuc pDNA was 
obtained in purified form from Plasmid Factory (Bielefeld, Germany). pDNA Cy5-labeling 
kit was obtained from Mirus Bio (Madison, WI, USA). Ready to use siRNA duplexes were 
obtained from Axolabs GmbH (Kulmbach, Germany): siGFP (sense: 5’-
AuAucAuGGccGAcAAGcAdTsdT-3’; antisense: 5’-UGCUUGUCGGCcAUGAuAU 
dTsdT-3’; small letters: 2’-methoxy; s: phosphorothioate) for silencing of eGFPLuc; siCtrl 
(sense: 5’-AuGuAuuGGccuGuAuuAGdTsdT-3’; antisense: 5’-
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CuAAuAcAGGCcAAuAcAU dTsdT-3’). Peptide modified sequences siGFP-Inf7 (sense: 
Inf7-ss-C6-5’-AuAucAuG GccGAcAAGcAdTsdT-3’; antisense: 5’-
UGCUUGUCGGCcAUGAuAUdTsdT-3’) and its control siCtrl-Inf7 (sense: Inf7-ss-C6-5’-
AuGuAuuGGccuGuAuuAGdTsdT-3’; antisense: 5’-CuAAuAcAGGCcAAuAcAUdTsdT-3’) 
were synthesized as published. [113] 
2.2 Oligomer synthesis methods 
2.2.1 Synthesis of polyamino acid building blocks 
The cationic building blocks Stp(Boc3)-Fmoc and Sph(Boc4)-Fmoc were synthesized as 
described before.[99, 100] Generally, starting with selective protection of the primary 
amines of TEPA (for Stp(Boc3)-Fmoc) or PEHA (for Sph(Boc4)-Fmoc) and the secondary 
amines by ethyl trifluoroacetate and di-tert butyl dicarbonate respectively, followed with 
deprotection of the primary amines with NaOH, the building block could be obtained by 
asymmetric functionalization of the terminal primary amine with Fmoc-Osu and succinic 
anhydride. 
2.2.2 Resin loading 
2.2.2.1 Loading of 2-chlorotrityl resin 
The desired amount of 2-chlorotrityl chloride resin (chloride loading 1.6 mmol/g) was 
placed in a syringe reactor and preswelled in dry DCM (10 mL/g resin) for 30 min, 
the DCM was discarded subsequently. A solution containing 0.4 eq mmol Fmoc-amino 
acid and 0.8 eq mmol DIPEA in dry DCM (10 mL) were added per gram resin and 
incubated for 1 h at RT. After disposal of the reaction mixture, the resin was 
incubated with a mixture of DCM/MeOH/DIPEA (10 mL/g resin; 80/15/5 v/v/v) for 30 
min at RT to cap residual reactive chloride functions. The resin was washed 5 times 
with DCM (10 mL/g resin) and part of the resin was separated for the loading 
determination. The rest resin was washed 3 times with DMF (10 mL/g resin) and treated 
5 times for 10 minutes with 20 % piperidine in DMF. Finally, the resin was washed 3 
times with DMF, 3 times with DCM, 3 times with n-hexane and dried under vacuum. In 
general, by this procedure resin loadings between 0.2 and 0.3 mmol/g were achieved. 
To avoid aggregation of the highly branched four-arm oligomers, a very low loaded resin 
have been obtained by using decreased amount of Fmoc-amino acid ( 0.2 eq), resulted 
in a very low resin loading around 0.1 mmol/g. 
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2.2.2.2 Loading determination 
For resin loading determination, an exact amount (about 10 mg) of vacuum-dried resin 
were react with 1 mL of 20 % piperidine in Eppendorf reaction tubes for 1 h at RT 
under shaking. After vortex and centrifugation, 25 µl of the supernatant were diluted with 
975 µl DMF. A solution of 20% piperidine in DMF acted as a blank. The absorption was 
measured at 301 nm using a Genesys 10S UV-VIS spectrophotometer (Thermo 
Scientific, Dreieich, Germany), and the resin loading was calculated using the following 
formula. 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 = 𝐹𝑆 (
𝑚𝑚𝑜𝑙
𝑔
) =
1000 ∙ 𝐴
𝑚 ∙ 𝜀 ∙ 𝐷
 
A: Absorbance; m: resin mass in mg; ε: molar extinction coefficient = 7800 L/(mol*cm); D: dilution factor (in 
this example: D=0,025) 
2.2.3 Standard solid-phase synthesis conditions 
2.2.3.1 General SPS process 
SPS represent as a sequential repeated process of coupling and deprotection. For a 
general Fmoc based SPS, the resin was incubated with a 4-fold excess of the 
appropriate pre-activated Fmoc amino acid identified by the target oligomer sequence for 
1 h at RT. The pre-activation of Fmoc amino acid was carried out with an equimolar of 
HOBt, PyBOP and two fold molar DIPEA. Fmoc deprotection was normally carries out 
by 10 min incubation with 20% piperidine in DMF for several times. Kaiser test was 
performed to determine the presence of free amines after each coupling and deprotection 
step.[114] In case of an unexpected result of the Kaiser test, the last coupling respectively 
deprotection step was repeated. After assembly of the full sequence, the desired product 
was cleaved from the resin and purified by SEC. 
2.2.3.2 Kaiser test 
Kaiser test was used to qualitatively determine the presence of free amines.[114] A 
small amount of sample of DCM washed resin was transferred to an Eppendorf 
reaction tube. One drop of each 80 % (w/v) phenol in EtOH, 5 % (w/v) ninhydrin in EtOH 
and 20 µM potassium cyanide (KCN) in pyridine were added. The tube was incubated 
at 99 °C for 4 min under shaking. The presence of free amines was indicated by a blue 
colored resin beads and solution (positive Kaiser test), while the remained colorless resin 
beads and light yellow solution indicate the absence of free amines (negative Kaiser test). 
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2.2.3.3 Oligomer cleavage 
The assembled conjugates was cleaved off the resin by incubation with 
TFA/DODT/TIS/H2O 94:1:2.5:2.5 (10 mL/g resin) for 90 min. The filtered cleavage 
solution was collected in a round-bottom flask and the resin was washed 3 times with TFA, 
3 times with DCM (10 mL/g resin). The combined solution was concentrated under 
reduced pressure to a final volume of approximately 1 mL and added dropwise to a pre-
cooled 50 mL MTBE/n-hexan (1/1 v/v) mixture, given out the precipitated crude product. 
After centrifugation for 15 min at 4000 RCF and 4 °C, the supernatant was discarded and 
the precipitate was dried with nitrogen. 
2.2.4 Oligomer synthesis 
2.2.4.1 Synthesis of three-arm oligomers 
The three arm oligomer 386 and 689 were synthesized as described before.[101, 109] 
Generally, 2-Chlorotrityl chloride resin preloaded with Fmoc-Cys(Trt)-OH was used to 
step-wisely coupled with building block Fmoc-Stp(Boc3)-OH, Fmoc-His(Trt)-OH, Fmoc-
Lys(Fmoc)-OH and Boc-Cys(Trt)-OH according to the required sequence under the 
general SPS procedure. 
2.2.4.2 Synthesis of PEGylated two- and four-arm oligomers with FolA ligands 
2-Chlorotrityl chloride resin preloaded with Fmoc-Lys(ivDde)-OH was used for the 
synthesis of PEGylated structures with ligands. The protected artificial oligoamino acid 
building block Fmoc-Stp(Boc3)-OH or Fmoc-Sph(Boc4)-OH and protected α-amino acids 
Fmoc-His(Trt)-OH, Fmoc-Tyr(OtBu)-OH, Fmoc-Lys(Fmoc)-OH and terminal Boc-
Cys(Trt)-OH were coupled stepwise to the deprotected α-amine of the preloaded Lys 
using 4 eq amino acid, 4 eq HOBt, 4 eq PyBop and 8 eq DIPEA in DCM/DMF and 1 h 
incubation time. The equivalents were calculated according to the free amines generated 
after the Fmoc deprotection. Fmoc deprotection was accomplished by 4 x 10 min 
incubation with 20% piperidine in DMF and twice with 20% piperidine in DMF containing 
2% DBU for 5 min. After each coupling and deprotection step the resin was washed three 
times with DMF and DCM, and a Kaiser test was performed. In case of an unexpected 
result of the Kaiser test, the last coupling respectively deprotection step was repeated. 
The ivDde group of the C-terminal lysine was removed by treating the resin 20-30 times 
with 2% hydrazine in DMF, the deprotection process was monitored by checking 
absorption of the reaction solution at 290 nm. Subsequently, at the deprotected ε-amine 
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of the C-terminal lysine a precise bifunctional Fmoc-N-amido-dPEG24-acid was attached 
followed by coupling of Fmoc-Glu-OtBu and N10-(Trifluoroacetyl)pteroic acid in case of the 
folic acid targeted oligomers or substitutes in case of the controls. Couplings of the PEG-
ligand segment were carried out under the same conditions as described above. For the 
folic acid containing oligomers, a deprotection of the trifluoroacetyl-group of pteroic acid 
was carried out using 25% aqueous ammonia solution/DMF (1:1) four times for 30 min. 
After each deprotection cycle, the resin was washed with DMF. After completion of the 
reaction, the resin was washed with DMF, DCM and n-hexane and dried in vacuo. The 
crude product was purified by SEC after cleavage. 
2.2.4.3 Synthesis of TNB-modified oligomers 
To generate corresponding TNB-modified oligomers, the unmodified oligomers were 
dissolved in deionized water, and treated with 10 eq of TCEP solution for 30 min in order 
to make sure that they are fully converted into the reduced thiol form, followed with adding 
of 10 eq DTNB stock solution (5 mM DTNB in 100 mM potassium phosphate buffer 
solution, pH 7.2 containing 0.1 mM EDTA), and reacted for another 2 h at room 
temperature. The reaction solution was then purified by SEC according to the general 
procedure described in 2.2.5.1. 
2.2.4.4 Synthesis of branched oleic acid containing oligomers 
2-Chlorotrityl chloride resin preloaded with Fmoc-Lys(ivDde)-OH was used for the 
synthesis of branched oligomers containing oleic acid. The assembly of the branched 
cationic backbone was carried out using the general SPS procedure, building block Fmoc-
Stp(Boc3)-OH, Fmoc-Lys(Fmoc)-OH and terminal Boc-Cys(Trt)-OH. After deproctection 
of ivDde, Fmoc-Lys(Fmoc)-OH and oleic acid were step-wisely coupled. The crude 
product was purified by SEC after cleavage. 
2.2.4.5 Synthesis of PEGylated targeted oleic acid containing oligomers 
2-Chlorotrityl chloride resin preloaded with Dde-Lys(Fmoc)-OH was used for the synthesis 
of PEGylated targeted oligomers containing oleic acid. Specifically, the assembly started 
with the coupling of PEG24 chain. After finishing assembly of the folic acid (or glutamic 
acid) ligand, the lysine α-Dde protection group was removed to continue the synthesis of 
the Stp backbone analogously as described in general SPS process. 
2.2.5 Oligomer purification and analytical characterization 
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2.2.5.1 Size-exclusion chromatography 
All oligomers were purified by size exclusion chromatography using an Äkta purifier 
system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) based on a P-900 solvent 
pump module, a UV-900 spectrophotometrical detector, a pH/C-900 conductivity module, 
a Frac-950 automated fractionator, a Sephadex G-10 column and 10 mM hydrochloric 
acid solution / acetonitrile 7:3 as solvent. The corresponding fractions were collected and 
lyophilized. 
2.2.5.2 1H-NMR 
1H NMR spectra were recorded using a Jeol JNMR-GX 400 (400 MHz) or JNMR-GX 500 
(500 MHz) without TMS as internal standard. All chemical shifts were calibrated to the 
residual proton signal of the solvent and are reported in ppm. Data are reported as s = 
singlet, d = doublet, t = triplet, m = multiplet. The spectra were analyzed using MestreNova 
(Ver. 9.0.1, MestReLab Research). 
2.2.5.3 RP-HPLC 
The purity of the oligomers was analyzed by RP-HPLC using a Waters HPLC system 
equipped with a Waters 600E multisolvent delivery system, a Waters 996 PDA detector 
and a Waters 717plus autosampler. As indicated, the compounds were analyzed 
using a Waters Sunfire C18 or Xbridge C18 column (5 µm, 4.6 x 150 mm) and a 
water/acetonitrile gradient (95:5 – 0:100) containing 0.1 % TFA. For the detection the 
extinction at 214 nm was monitored. 
2.2.6 Buffer capacity of oligomers by alkalimetric titrations 
The oligomer sample, containing 15 µmol protonable amines, was diluted in a total volume 
of 3.5 mL NaCl solution (50 mM) and the pH was adjusted to 2 by addition of hydrochloric 
acid. Afterwards, a back titration with 0.05 M NaOH was performed with an automatic 
titration system (Titrando 905 from Metrohm, Germany) equipped with a Biotrode pH 
electrode (METROHM GmbH & Co. KG, Filderstadt, Germany), until a pH of 11 was 
reached. To distinguish oligomer and solvent effects, a control titration of 50 mM sodium 
chloride solution without oligomer was performed. Volume differences (ΔV) between 
defined pH values were determined. Total endolysosomal buffer capacity C in the pH 
range between 5 and 7.4 was calculated according to the following formula: 
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CpH 5−pH 7.4 =
[∆𝑉(Sample)pH 5−pH 7.4 −  ∆𝑉(NaCl)pH 5−pH 7.4]  ∙ 50 mM
15 μmoles
 ∙ 100% 
2.3 Polyplex formation and biophysical analysis 
2.3.1 Polyplex formation 
2.3.1.1 General pDNA and siRNA polyplex formation 
pDNA or siRNA and oligomers at indicated nitrogen/phosphate (N/P) ratios were 
separately diluted with equal volumes of 20 mM HEPES buffered 5% glucose pH 7.4 
(HBG). Only protonatable nitrogens were considered in the N/P calculations. The N/P 
ratio was calculated according to the cationic amine groups (N number) of the Stp and 
Sph building blocks and N-terminal first amine of cysteine residues to anionic phosphate 
groups (P number) in pDNA or siRNA. Here the amines of the imidazole group in Histidine 
were not taken into account when calculating the N numbers, as they are not protonated 
at pH 7.4. The polycation solution was added to the nucleic acid, mixed by rapid pipetting 
and incubated for 40 min at RT under air exposure to led oxidative disulfide formation. 
2.3.1.2 Formation of targeted combinatorial siRNA polyplexes (TCP) 
siRNA polyplexes for transfections were prepared (unless otherwise mentioned) as 
follows: at the indicated N/P ratios, 500 ng of siRNA was diluted in 10 μL of 20 mM HEPES 
buffered 5% glucose pH 7.4 (HBG), and the calculated amount of the two oligomers for 
the designated [TNB-modified oligomer / unmodified mercapto-form of oligomer] molar 
ratio, were separately diluted in 5 μL of HBG. The solution of the first TNB-modified 
oligomer was added to the siRNA solution and mixed by rapid pipetting (at least 5 times) 
to obtain 15 μL of binary siRNA polyplex solution. After 30 min in the closed Eppendorf 
reaction tube at room temperature, the solution of the second oligomer was added to the 
siRNA polyplex solution, to obtain 20 μL of siRNA polyplexes solution in total. The solution 
was placed for further 40 min at room temperature for disulfide formation. Unless indicated 
differently (Figure 6.6 only), the same TCP siRNA mixing sequence was applied. 
TCP polyplex calculations. Calculations of the individual two oligomers used at N/P 16 
in formation of TCPs at indicated molar ratios were made as follows. Protonatable 
nitrogens (N) for the applied oligomers in the current work were calculated excluding 
histidine Ns (defined as unprotonated at pH 7.4): N=29 for 386/769, N=29 for 689/770, 
N=68 for 709/873, N=34 for 717/874. The required molar amine amounts of oligomers at 
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N/P 16 were calculated, which are 24.88 nmol nitrogens (N) for 500 ng siRNA (in 
transfection). For size measurements 10µg siRNA were used, corresponding to 498 nmol 
N. 
For the following calculation of the molar amount of each oligomer, general formulas were 
applied as follows: 
1) N/Ptotal = 16= N/Pa+ N/Pb ("a" and "b" to stand for the two oligomers). 
2) Total molar amount of nitrogen Mtotal=Na*Ma+ Nb*Mb, here N stands for the number of 
protonatable nitrogens, while M stands for the molar amount. 
3) The molar ratio of oligomers Ma/Mb=Ra/Rb. R stands for the ratio of each oligomer (1:1 
in the majority of cases). 
4) Calculation of the molar amount of each oligomer: Ma=16*Mtotal*Na/(Na+Nb*Rb/Ra), and 
Mb=16*Mtotal*Nb/(Na*Ra/Rb+Nb). 
5) The individual N/P ratio for each oligomer (at N/Ptotal = 16): N/Pa=16*Na/(Na+Nb*Rb/Ra), 
and N/Pb=16*Nb/(Na*Ra/Rb+Nb). 
As an example of TCP1 386/873 at molar ratio 40:60, the individual N/P for 386 is 
16*29/(29+68*60/40)=3.5, for 873 it is 16*68/(29*40/60+68)=12.5, and the molar amount 
M for 386 is 24.88*29/(29+68*60/40)=5.45 nmol for 500 ng siRNA. 
Depending on the selected molar ratios and TCPs, the final molar ratios of thiol SH /TNB 
will differ. At oligomer molar 1:1 ratio, SH/TNB are 3:4 for TCP1, 2:3 for TCP2, 4:3 forTCP3, 
and 3:2 for TCP4.   
2.3.2 Ethidium bromide compaction assay 
A Cary Eclipse spectrophotometer (Varian, Germany) was used for the quantification of 
ethidium bromide (EtBr) fluorescence at the excitation wavelength λex = 510 nm and 
emission wavelength λem = 590 nm. pDNA polyplexes were incubated with 2 µg pDNA 
and the oligomer at N/P 12 in 200 µL HBG for 40 minutes. siRNA polyplexes were 
incubated with 5 µg siRNA and the oligomer at N/P 20 in 200 µL HBG for 40 minutes. 
Before the measurement 800µL of EtBr solution (c = 0.4 µg/mL) was added. 200 µL HBG 
buffer with 800µL of EtBr solution (c = 0.4 µg/mL) was used as blank. 200µL of nucleic 
acid solution (2µg pDNA or 5µg siRNA) + 800µL of EtBr solution (c = 0.4 µg/mL) was 
assigned to 100%. The fluorescence intensity of EtBr measured after 3 minutes of 
incubation was determined in relation to the 100% value. Triplicates were measured. 
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2.3.3 Electrophoretic mobility shift assay 
A 1% (w/v) agarose gel for pDNA analyses and a 2.5% (w/v) agarose gel for siRNA 
analyses were prepared by dissolving agarose in TBE buffer (Trizma base 10.8 g, boric 
acid 5.5 g, disodium EDTA 0.75 g, and 1 L of water). After adding of GelRed™ (Biotium, 
Hayward, U.S.A.), the agarose gel was formed in the electrophoresis unit. Polyplexes 
containing 200 ng pDNA or 500 ng siRNA were formed and placed into the sample 
pockets after adding of 4 μL loading buffer ( 6 mL of glycerine, 1.2 mL of 0.5 M EDTA, 2.8 
mL of H2O, 0.02 g of bromophenol blue). Electrophoresis was performed at 120 V for 80 
min in case of pDNA polyplexes and for 40 min in case of siRNA polyplexes. 
2.3.4 Particle size and zeta potential 
Particle size and zeta potential of polyplexes were measured by dynamic laser-light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, U.K.). 
Polyplexes containing 10 μg of nucleic acid in a total volume of 50 μL were further diluted 
1:20 with 20mM HEPES pH 7.4 buffer before measuring in a folded capillary cell 
(DTS1060 or DTS1070). For size measurements, each sample was measured 3 times 
with 10 subruns at 25 °C. Zeta potentials were calculated by the Smoluchowski equation, 
each samples was measured 3 times with 10 to 30 subruns at 25 °C. 
2.4 Cell culture 
All cell culture work was carried out by Katharina Müller, Ana Krhac Levacic, Dian-Jang 
Lee, and Dr. Petra Kos (Pharmaceutical Biotechnology, LMU).  
Mouse neuroblastoma cells Neuro2a WT cells and Neuro2a/eGFPLuc cells were cultured 
in Dulbecco's modified Eagle's medium. Human KB WT cells and KB/eGFPLuc cells were 
cultured in folate free RPMI-1640 medium. Both medium were supplemented with 10% 
fetal bovine calf serum (FBS), 4 mM stable glutamine, 100 U/mL penicillin, and 100 μg/mL 
streptomycin at 37 °C in 5% CO2. Cells were collected by using a trypsin-EDTA (0.25%) 
solution and the cell suspension was seeded at the required concentration for each 
experiment. 
2.4.1 Luciferase gene transfer 
For folate targeted polyplexes, KB cells were seeded in 96-well plates with 8000 KB 
cells/well 24 h before pDNA transfection. Before treatment, the cell culture medium was 
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replaced with 80 μL fresh medium containing 10% FBS. Polyplexes containing 200 ng 
pCMVLuc formed at different protonatable nitrogen/phosphate (N/P) ratios in a total 
volume of 20 μL HBG were added to each well and incubated at 37 °C. Medium was 
replaced 45 min after transfection by fresh medium or chloroquine (0.1 mM) containing 
medium. After 4 h incubation at 37 °C, medium was changed again by fresh medium, and 
cells were further cultured for 24 h after initial transfection. For non-targeted pDNA 
polyplexes containing 200 ng pCMVLuc formed at different protonatable 
nitrogen/phosphate (N/P) with branched fatty acid containing oligomers, the luciferase 
gene transfer experiments were performed with 10000 Neuro2a WT cells/well. 
Alternatively, after adding the polyplexes, the cells were further cultured for 24 h at 37 °C 
without medium change. 
Cells were treated with 100 μL cell lysis buffer. Luciferase activity was measured using a 
luciferin-LAR buffer solution and a Centro LB 960 plate reader luminometer (Berthold 
Technologies, Bad Wildbad, Germany). Transfection efficiency was evaluated as relative 
light units (RLU) per well. All experiments were performed in quintuplicates. 
2.4.2 Metabolic activity of pDNA transfected cells (MTT assay) 
To detect metabolic activity of pDNA transfected cells, the transfection experiments were 
performed as described in 2.4.1. After 24 h of initial transfection, 10 μl of MTT (5 mg/ml) 
was added to each well and incubated for 2 h at 37 °C for the formation of the dark purple 
formazane product. After removal of unreacted dye and medium, the 96-well plates were 
stored at −80 °C for at least one hour. Then 100 μL DMSO per well were added to dissolve 
the purple formazan product. The absorbance was measured at 590 nm with 630 nm as 
the reference wavelength, using microplate reader (Tecan Spectrafluor Plus, Tecan, 
Switzerland). The relative cell viability (%) related to control wells treated only with 20 μL 
HBG was calculated as ([A] test/[A] control) × 100%. All experiments were performed in 
quintuplicates. 
2.4.3 Gene silencing with siRNA 
For folate targeted polyplexes, gene silencing experiments were performed in 
KB/eGFPLuc cells. Polyplexes were formed with the unmodified siRNA against eGFP for 
silencing the eGFPLuc fusion protein, its control sequence siCtrl, and the lytic peptide 
modified Inf7-siGFP, with its control sequence Inf7-siCtrl. Cells were seeded in 96-well 
plates with 4000 KB/eGFPLuc cells/well 24 h before siRNA silencing. The cell culture 
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medium was replaced with 80 μL fresh medium containing 10% FBS before treatment. 
Polyplexes containing 200 ng siRNA formed at different protonatable nitrogen/phosphate 
(N/P) ratios in a total volume of 20 μL HBG were added to each well and incubated at 
37 °C. 45 min after transfection medium was replaced by fresh medium, and cells were 
further cultured for 48 h after initial transfection. For non-targeted polyplexes, experiments 
were performed with polyplexes containing 500 ng siGFP or siCtrl in 5000 
Neuro2A/eGFPLuc cells respectively, cells were further cultured for 48 h after initial 
transfection. Luciferase activity was determined as described above. The relative light 
units (RLU) were presented as percentage of the luciferase gene expression obtained 
with buffer treated control cells. All experiments were performed in triplicates. 
2.4.4 Flow cytometry 
Cellular internalization. KB WT or KB/eGFPLuc cells were seeded into 24-well plates 
coated with collagen at a density of 5∗104 cells/well. After 24 h, culture medium was 
replaced with 400 μL fresh growth medium. pDNA polyplexes (N/P 12, for oligomers #29-
32 and #35-42 polyplexes were formed at N/P 3) containing 1 μg pDNA (including 20% 
Cy5-labeled pDNA) or siRNA polyplexes (N/P 12) containing 1.35 μg siRNA (including 20% 
Cy5-labeled siRNA) in 100 μL HBG were added to each well and incubated at 37 °C for 
45 min. Afterwards, cells were washed with 500 μL PBS containing 500 IU of heparin on 
ice for 15 min to remove any polyplexes sticking to the cell surface. After an additional 
PBS washing step, cells were detached with trypsin/EDTA and resuspended in PBS with 
10% FBS. Cellular internalization of the polyplexes was measured by excitation of Cy5 at 
635 nm and detection of emission at 665 nm. Cells were appropriately gated by 
forward/sideward scatter and pulse width for exclusion of doublets. DAPI (4’,6-diamidino-
2-phenylindole) was used to discriminate between viable and dead cells. Data were 
recorded by Cyan™ ADP flow Cytometer (Dako, Hamburg, Germany) using Summit™ 
acquisition software (Summit, Jamesville, NY, USA) and analyzed by FlowJo® 7.6.5 flow 
cytometric analysis software. All experiments were performed in triplicates. 
2.5 Statistical analysis 
Results are presented as mean ± standard deviation (SD). The number of replicates is 
indicated in the corresponding methods section. 
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3 Results 
3.1 Combinatorial optimization of sequence-defined oligo(ethanamino)-amides 
for folate receptor-targeted pDNA and siRNA delivery 
As discussed in the introduction section, successful gene therapy strategies require 
efficient and safe delivery methods for the transfer of therapeutic nucleic acids into the 
target cells. An ideal nucleic acid carrier has to overcome many extracellular and 
intracellular barriers. Integrated functional microdomains may accomplish these different 
tasks, including nucleic acid complexation, nanoparticle shielding and targeting, cellular 
uptake, endosomal escape and nucleic acid release at the intracellular target site.[115-
118] Polymeric materials, like polyethylenimine (PEI), dendrimers, chitosan, or others 
have been widely investigated as nucleic acid carriers.[119-126] However, heterogeneity 
and polydispersity of polymers remain critical issues that have to be carefully considered 
in structure-activity relationship assessments, manufacturing, and in clinical studies. 
Therefore, polymers with precise molecular structure and site-specific modification [49, 
52, 95, 96] are preferred in the further development of multifunctional carriers for gene 
delivery.  
Our group has developed sequence-defined cationic oligomers by solid-phase assisted 
synthesis using artificial amino acids as building blocks comprising repeats of the 1,2-
diaminoethane motif.[99-102, 104] The diaminoethane motif was previously discovered 
as a key chemical structure providing PEI and related transfection polymers an excellent 
nucleic acid binding and endosomal buffering capacity.[21, 55, 123, 124, 127-129] The 
artificial oligoamino acids, such as succinoyl-tetraethylene pentamine (Stp) and succinoyl-
pentaethylene hexamine (Sph), were used in combination with natural α-amino acids and 
other building blocks to assemble sequence-defined oligoamino amides with different 
topologies and multiple functional domains.[23, 103, 105, 109, 113, 130-131] Previous 
studies by several groups showed that histidines can provide additional pH-buffering via 
the protonation of imidazole groups, facilitating endosomal escape.[22, 23, 109, 132, 133] 
Insertion of hydrophobic amino acids such as tyrosine enhanced the stability as well as 
endosomal escape of polyplexes.[105, 134-137] For the targeted delivery of nucleic acids 
to the site of action, shielding domains such as polyethylene glycol (PEG) to minimize 
unspecific interactions [138-141] and targeting ligands to mediate specific cellular binding 
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and uptake can be incorporated. In this respect, multiple functionalizations of oligomers 
may meet the requirements to overcome the multiple barriers of gene delivery.[124, 142, 
143] 
For this purpose, we designed and synthesized a library of forty-two sequence-defined 
oligomers comprising the artificial polyamino acids Stp and Sph for nucleic acid 
complexation, monodisperse polyethylene glycol (PEG) for surface shielding, and folic 
acid for receptor-specific cellular uptake. Two topologies of branched cationic oligomers 
(two-arms, four-arms) based on Stp or Sph monomers, optionally containing endosomal 
buffering histidines and/or hydrophobic tyrosine trimers were designed and systematically 
evaluated for properties in pDNA and siRNA delivery. We also focused on the ligand-
dependency of the nucleic acid transfer by comparing with analogous folate-free 
oligomers. 
3.1.1 Design and synthesis of folate targeted sequence-defined oligomers 
The starting point of the current study was oligomer 356, a branched two-arm cationic 
domain of Stp units linked with a PEG segment and a FolA ligand (see Figure 3.1) as 
folic acid receptor-specific nucleic acid carrier.[113] This precise oligoamino amide 
sequence consists of folate linked with a chain of twenty-four ethylene glycol monomers, 
a branching α,ε-amidated lysine, and two arms of each four Stp units followed by a 
terminal cysteine unit. Within polyplexes, the terminal cysteines provide stabilization by 
disulfide crosslinks and were found strictly required for stable polyplex formation and 
transfection.[113] The high PEG content (24 ethylene glycol units in comparison to 24 
protonatable aminoethane units) negatively affects the endosomolytic property and the 
nucleic acid compaction process. For 356 pDNA polyplexes, the addition of 
lysosomotropic chloroquine is required for efficient gene transfer. In siRNA transfections, 
modification of siRNA with the endosomolytic Inf7 peptide [29, 144] was critically required 
for gene silencing. With regard to nucleic acid compaction, the high PEG content of 356 
and related two-arm oligomers prevents intermolecular nucleic acid compaction, resulting 
in very small unimolecular siRNA complexes on the one hand,[113] and loosely 
compacted pDNA complexes on the other hand.[107] The latter could be overcome by 
reducing the PEG content of polyplexes.[109] Four-arm oligomers (without PEG but with 
double number of Stp or Sph units) had been found as very effective pDNA compacting 
carriers.[23, 100] 
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Figure 3.1 Overview of the synthesized PEGylated oligomers, their topologies, sequences, and their 
numbers within the current manuscript. L stands for the targeting ligand or the corresponding negative 
control (FolA, folic acid; A, alanine; E, glutamate; acetate); PAA, polyamino acid (Stp, succinoyl-
tetraethylene-pentamine; Sph, succinoyl-pentaethylene-hexamine); PEG, polyethylene glycol; K, lysine; H, 
histidine; Y, tyrosine; C, cysteine.  K-( and K-[ refer to branchings by α- and ε-amino modification of lysines. 
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The new library of forty-two oligomers was synthesized using solid-phase assisted 
synthesis and contained the following systematic variations (Figure 3.1): (1) the type of 
artificial oligoamino acid building block (succinoyl tetraethylene pentamine (Stp) 
containing five nitrogens, or succinoyl pentaethylene hexamine (Sph) containing six 
nitrogens), (2) the topology (two-arm or four-arm cationic core for nucleic acid compaction), 
(3) additional histidines for enhanced endosomal pH-buffering and/or (4) terminal tyrosine 
trimers for enhanced stability of the formed polyplexes. Folic acid was chosen as small 
molecule targeting ligand due to its high affinity for folate receptors, which are commonly 
over-expressed on the cell surface of many human cancer types [145, 146]. To investigate 
the targeting ligand dependency, we incorporated negative control substitutes. For most 
of the oligomers, we used glutamic acid in the ligand negative control, as the glutamic 
acid residue is a fragment of folate with the same negative charge. For some oligomers 
synthesized in an early project phase, we used alanine, similar as in the previous 
published 356 oligomer study,[113] or acetate (as a small noncharged residue) as 
alternative negative control ligands. A full list of detailed sequences and the internal library 
identification number could be find in Table 6.1. 
3.1.2 Biophysical properties 
To investigate the binding behavior of these oligomers with nucleic acids (pDNA or siRNA), 
agarose gel shift assays of the formed polyplexes were performed (Figure 3.2, 6.1, 6.2). 
For pDNA polyplexes, all PEGylated oligomers with a combination of cationic building 
blocks and terminal cysteines showed effective pDNA binding already at a low N/P of 6, 
as evidenced by retardation in the agarose gel electrophoresis. This was largely 
independent from the cationic backbone, histidine and tyrosine trimer modifications 
(Figure 3.2A, 6.1). Well consistent with the smaller size of siRNA as compared to 
pDNA,[151] siRNA polyplexes displayed less stability in the agarose gel shift assay 
(Figure 3.2B, 6.2).  
For the majority of oligomers, an N/P ratio of 12 or higher was required for stable nucleic 
acid complexation indicated by complete retardation in the agarose gels. Interestingly, 
integration of tyrosine trimers (#9-16, #35-36) did not promote polyplex stability. This 
observation apparently contradicts our previous studies with non-PEGylated siRNA 
lipopolyplexes.[105] It can, however, be explained by the presence of PEG in the present 
oligomers. PEG increases solubility and thus counteracts the hydrophobic interactions of 
tyrosine trimer domains. On the other hand, insertion of histidines slightly increased the 
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binding ability of the corresponding oligomers.  
The ability of oligomers to complex and compact nucleic acids was further evaluated by 
an ethidium bromide exclusion assay performed at N/P 12 (Figure 3.3). The larger 
cationic backbone provided by four-arm oligomers resulted in a higher compaction 
compared to two-arm oligomers. Within each subclass, oligomers with four cationic 
building blocks per arm bound pDNA slightly better than those with only three building 
blocks (Figure 3.3A). With regard to siRNA, the best compaction (monitored by dye 
exclusion) was observed by using the basic two-arm (#1-4) and four-arm (#21-28) 
oligomers without further integration of histidines and tyrosine trimers (Figure 3.3B). A 
tendency towards decreased complexation ability with increased insertion of domains into 
the cationic backbone was found, especially for the two-arm-H-Y3 group. These results 
suggest the cationic charge density of the backbone as most critical point for nucleic acid 
interaction. 
 
Figure 3.2 Gel retardation assays of selected pDNA (A) or siRNA (B) polyplexes formed in HBG at the 
indicated different N/P ratios. Left lanes: free pDNA or siRNA, respectively. A full set of data for all 
oligomers is presented in Figure 6.1 (pDNA) and Figure 6.2 (siRNA).  
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Figure 3.3 Nucleic acid compaction ability of synthesized oligomers as detected by an ethidium bromide 
exclusion assay. A) pDNA compaction and B) siRNA compaction by different oligomers at N/P 12. Linear 
22kDa PEI (LPEI) N/P 6 was used as positive control. The fluorescence intensity of EtBr was determined 
in relation to the 100% value (samples with only pDNA or siRNA) with a blank solution of HBG buffer. Data 
were presented as mean + SD (n=3). 
Other important biophysical parameters for the evaluation of suitable polyplexes are 
particle size and zeta potential (Table 3.1). pDNA polyplexes (in contrast to small siRNA 
nanoplexes)[131] can be easily analyzed by dynamic laser light scattering (DLS). Most of 
the oligomers formed nanoparticles with a Z-average diameter between 100-300 nm and 
zeta potentials between +5 to +20 mV. However, some FolA conjugates (#10, #12, #14, 
#16, #18, #20, #30, #32) showed increased size compared to their corresponding control 
oligomers. Especially for #10 and #12 a low zeta potential and polyplex aggregation with 
Z-averages above 1000 nm was observed. Apparently the combination of exposed 
hydrophobic FolA ligands with a reduced electrostatic repulsion between nanoparticles 
causes colloidal instability and flocculation of polyplexes, which is consistent with other 
related observations.[148] Oligomers with additional cationic building blocks showed a 
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slightly higher zeta potential compared to their analogs with less cationic building blocks. 
Four arm oligomers generally showed a higher zeta potential (between 13- 20 mV) than 
two-arm oligomers (below 15 mV). 
Table 3.1. Particle size (Z-average) and zeta potential of pDNA polyplexes formed at N/P 12 in HBG buffer 
measured by DLS. Polyplexes were diluted 1:20 with HEPES buffer before measurement. Data were 
presented as mean ± SD (n=3). 
No. 
pDNA polyplexes 
Z-average (nm) PDI Zeta potential (mV) 
#1 104.6±6.0 0.34±0.06 15.0±0.6 
#2 143.4±1.2 0.12±0.01 13.0±0.1 
#3 149.0±3.8 0.46±0.01 14.4±0.6 
#4 163.7±1.8 0.22±0.03 13.2±0.7 
#5 570.6±125.2 0.23±0.04 2.1±0.04 
#6 525.1±78.8 0.20±0.01 0.2±0.2 
#7 219.9±8.4 0.14±0.03 6.7±0.3 
#8 491.9±57.3 0.14±0.03 6.1±0.1 
#9 165.1±1.5 0.33±0.3 4.8±0.2 
#10 1099±177.2 0.51±0.04 3.2±0.2 
#11 156.5±3.0 0.28±0.002 6.5±0.6 
#12 1503±42.3 0.54±0.12 6.1±0.4 
#13 344.6±59.0 0.54±0.05 6.4±0.6 
#14 641.5±133.1 0.20±0.02 6.9±0.8 
#15 248.9±40.8 0.50±0.06 8.0±0.1 
#16 484.5±68.9 0.18±0.05 8.7±0.3 
#17 163.8±10.5 0.10±0.001 5.5±1.2 
#18 520.0±75.6 0.13±0.03 6.6±0.2 
#19 132.3±1.5 0.12±0.02 8.2±0.1 
#20 368.0±48.4 0.11±0.01 10.1±0.6 
#21 177.3±3.5 0.37±0.02 13.1±0.9 
#22 561.5±29.1 0.34±0.03 14.1±0.3 
#23 147.6±0.9 0.25±0.01 15.3±0.8 
#24 198.5±1.2 0.13±0.003 17.5±0.5 
#25 144.9±2.7 0.45±0.02 15.1±0.6 
#26 136.9±0.7 0.09±0.004 15.2±0.5 
#27 114.1±1.1 0.35±0.01 17.8±1.5 
#28 120.3±2.9 0.12±0.01 20.4±0.5 
#29 140.8±0.2 0.31±0.02 14.1±0.5 
#30 576.7±146.9 0.27±0.03 13.5±0.3 
#31 132.5±2.3 0.24±0.01 14.1±0.4 
#32 673.7±94.4 0.28±0.02 14.8±0.3 
#33 125.6±2.82 0.39±0.01 13.9±0.4 
#34 156.1±4.4 0.10±0.01 16.0±0.6 
#35 125.2±4.9 0.15±0.02 14.1±0.6 
#36 123.2±2.0 0.12±0.01 17.6±0.2 
#37 120.8±2.0 0.16±0.01 15.2±0.2 
#38 113.7±1.1 0.12±0.01 19.5±0.6 
#39 130.7±1.6 0.26±0.01 15.6±0.7 
#40 164.9±2.2 0.13±0.02 19.2±0.9 
#41 150.5±1.6 0.30±0.02 16.5±0.5 
#42 122.7±2.9 0.13±0.02 20.8±0.2 
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Next, we investigated the buffer capacity in the physiological pH range between 
extracellular and endolysosomal environment (between pH 7.4 and pH 5) for selected 
oligomers using alkalimetric back titration (Table 3.2). The two-arm Stp oligomers #5 and 
#7 modified with histidines exhibited the by far highest buffering capacity. For four-arm 
oligomers, the highest buffer capacity was found for the histidine containing oligomers 
#29 and #31. 
Table 3.2 Total buffer capacity of selected oligomers between pH 5.0 to 7.4 measured by acidification to 
pH 2 and back titration with NaOH. 
Oligomer Buffer capacity 
#2 21.9% 
#4 24.5% 
#5 29.5% 
#7 29.0% 
#21 20.2% 
#23 18.3% 
#25 19.7% 
#27 19.0% 
#29 29.1% 
#31 25.8% 
#33 21.6% 
 
3.1.3 pDNA transfection 
The new oligomers (without or with PEG-linked folate as targeting ligand) were used for 
pDNA transfection of folate receptor-rich KB cells (Figure 3.4, 6.3). Standard 
transfections with the displayed nonshielding positive control (LPEI polyplexes) include 
incubation of cells with transfection complexes for a 4 h period longer than in case of 
targeted polyplexes, to enable sufficient cell binding and uptake. To verify the role of the 
faster receptor-mediated uptake in the transfection process, [113, 122, 149]  KB cells were 
incubated with the targeted polyplexes for a reduced period of only 45 min, after which 
the medium containing the non-bound transfection complexes was exchanged. 
Transfected cells were further incubated for 24 h with fresh media. The transfection results 
with selected examples of two-arm oligomers (matched pairs with or without folate 
targeting ligands) are displayed in Figure 3.4 (the complete set of data is presented in 
Figure 6.3). Every transfection was performed in the absence or 4 h presence of the 
endolysosomotropic agent chloroquine, which had been previously found to facilitate 
endosomal escape of entrapped polyplexes.[150] Comparison of transfection levels 
plus/minus chloroquine provided a measure of different intracellular transport problems 
for the individual oligomers. Our previously described Stp two-arm oligomer 356 mediated 
efficient gene transfer only with the help of chloroquine, suggesting that endosomal 
Results 
 
 
 
33 
 
escape represented a serious bottleneck which still had to be overcome. Also oligomers 
substituted with the larger building block Sph (e.g. #2) displayed this strong limitation. An 
analogous Stp two-arm oligomer with integrated histidines (#6) displayed a greatly 
improved pDNA transfection efficacy. The transgene expression levels in the absence of 
chloroquine equaled those of 356 in the presence of chloroquine. The addition of 
chloroquine further (approximately 10-fold) increased luciferase activity, consistent with 
our previous studies using different targeting ligands.[23, 109]  
The alternative modification of the Stp oligomer 356 with tyrosine trimers (#10) showed 
very low gene transfer activity with or without chloroquine. In contrast, the Sph oligomer 
#14 with tyrosine trimers exhibited an enhanced transfection activity as compared to the 
tyrosine free analog #2; effective gene transfer without chloroquine was observed at N/P 
12 and higher. The by far highest transgene expression (approx. 100.000-fold above 
background) was achieved with the Stp-based FolA-targeted two-arm oligomer (#18) by 
combined histidine and tyrosine trimer incorporation. Importantly, all negative control 
analogs lacking the targeting ligand folic acid showed negligible gene transfer activity. 
Regarding four-arm oligomers (Figure 3.4B), a similar tendency could be observed. The 
basic four-arm Stp oligomer without histidines or tyrosine trimers (#22) could already 
mediate moderate gene transfer without chloroquine, presumably as a result of the higher 
molecular fraction with cationic charge. However, chloroquine still significantly improved 
the transfection efficiency. For oligomer #26 based on Sph, the transfection activity 
without chloroquine also improved compared to the two-arm analog (#2). After 
modification with histidines, the transfection efficiency of the targeted oligomers (#30, #34) 
was greatly improved and similar efficacy could be achieved in transfections without or 
with chloroquine. Surprisingly, also the non-targeted oligomer #29 was moderately active 
at low N/P ratio. Consistent with the observation for two-arm oligomers, the modification 
of four-arm oligomers with tyrosine trimers alone (#35, #36) did not enhance pDNA 
delivery efficiency. Finally, four-arm oligomers were modified with a combination of 
histidines and tyrosine trimers. Non-targeted oligomer #39 showed medium gene transfer 
without chloroquine, and decreased transfection efficiency with chloroquine. The highest 
transfection activity of all four-arm oligomers could be achieved by oligomer #40 at the 
low N/P 3, and the transfection efficiency dramatically decreased with increased oligomer 
amount for toxicity reasons as explained below. Again, the control oligomers lacking the 
targeting folate showed low transfection efficiency compared to the folate containing 
oligomers. 
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Figure 3.4 Gene transfer in folate receptor expressing KB cells with selected examples of A) two-arm and 
B) four-arm oligomers. The lane FolA Ligand (- or +) refers to the absence or presence of folate ligand 
within the indicated oligomer. Luciferase pDNA oligomer polyplexes formed at N/P 3, 6, 12 or 24 were 
incubated with KB cells for the short period of 45 min, followed by replacement of transfection medium by 
fresh medium with (black bars) or without (grey bars) chloroquine for 4 h additional incubation before 
another medium exchange. LPEI polyplexes (at N/P 6, incubation with cells for a 4 h longer period before 
medium exchange) were set as the positive control. Luciferase activities at 24 h after transfection are 
presented in relative light units (RLU) as the mean + SD (n=5). A full set of data for all oligomers is 
presented in Figure 6.3. The experiments were performed by Ana Krhac Levacic and Dr. Petra Kos 
(Pharmaceutical Biotechnology, LMU Munich). 
In parallel to the gene transfer studies, metabolic activities of KB cells were evaluated by 
an MTT assay after transfection with the pDNA polyplexes. Importantly, only the four-arm 
oligomers containing tyrosine trimers (#35-42) showed obvious toxicity at higher N/P 
ratios (Figure 3.5B), which correlated well with the transfection data. Presumably, the 
increased hydrophobicity caused by the higher number of tyrosines in four-arm oligomers 
led to increased cytotoxicity. A slight toxicity could be observed for #32 (four-arm oligomer 
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containing histidines) at higher N/P of 12 and 24 (Figure 6.4). All other tested pDNA 
polyplexes did not cause toxicity, whereas the 4 h co-incubation with chloroquine triggered 
a slight reduction of cell viability after transfection (Figure 3.5A, 6.4). 
 
Figure 3.5 Metabolic activities of KB cells after transfection with the pDNA polyplexes as evaluated by an 
MTT assay. pDNA/oligomer polyplexes formed at N/P 3, 6, 12 or 24 were incubated with KB cells for 45 
min, followed by replacement of fresh medium with (black bars) or without (grey bars) chloroquine for 4 h 
additional incubation before another medium exchange. LPEI polyplexes (at N/P 6, incubation with cells 
for 4 h longer period before medium exchange) were set as the reference. Metabolic activities (%) were 
presented as the percentage relative to the buffer treated control cells. The data are shown as mean + SD 
(n=5). A full set of data for all oligomer polyplexes is presented in Figure 6.4. The experiments were 
performed by Ana Krhac Levacic and Dr. Petra Kos (Pharmaceutical Biotechnology, LMU Munich). 
 
Cellular uptake of pDNA polyplexes was investigated by flow cytometry using polyplexes 
formed with Cy5-labeled pDNA (Figure 3.6). Based on the transfection results, the 
majority of polyplexes were formed at N/P 12. For four-arm oligomers which displayed 
toxicity at higher N/P ratios, the optimum at lower N/P of 3 was chosen for the uptake 
study (Figure 3.7). In all cases folate-targeted oligomers mediated a higher cellular 
uptake than polyplexes of non-targeted control oligomer. This beneficial uptake of 
targeted polyplexes was consistent with the transfection data and confirmed the targeting 
effect. 
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Figure 3.6 Cellular internalization of selected Cy5-labeled pDNA (N/P 12) polyplexes after 45 min 
determined by flow cytometry. The intensity of the Cy5 signal indicates the amount of polyplexes being 
internalized by KB cells. Red curve, HBG buffer only treated cells; orange curve, folate containing 
oligomers treated cells; and blue curve, ligand free control oligomers treated cells. All experiments were 
performed in triplicate. The experiment was performed by Ana Krhac Levacic (PhD student, 
Pharmaceutical Biotechnology, LMU Munich). 
 
Figure 3.7 Cellular internalization of selected Cy5-labeled pDNA (N/P 3) polyplexes after 45 min 
determined by flow cytometry. The intensity of the Cy5 signal indicates the amount of polyplexes being 
internalized by KB cells. Red curve, HBG buffer only treated cells; orange curve, folate containing 
oligomers treated cells; and blue curve, ligand free control oligomers treated cells. All experiments were 
performed in triplicate. The experiment was performed by Ana Krhac Levacic (PhD student, 
Pharmaceutical Biotechnology, LMU Munich). 
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3.1.4 siRNA transfection 
The oligomer library was also tested for its gene silencing ability with siRNA using KB-
eGFPLuc cells. Figure 3.8 and 3.9 present results with selected two-arm or four-arm 
oligomers, respectively, Figure 6.5 presents the whole set of data. In this eGFP-luciferase 
gene silencing screen, FolA ligand containing oligomers were compared with ligand-free 
controls, and the specific siGFP was compared with control siRNA siCtrl. In addition, 
based on our previous studies with oligomer 356,[113] siRNA modified with the 
endosomolytic Inf7 peptide was used to facilitate endosomal escape of polyplexes. As 
expected, oligomer 356 showed efficient gene silencing with siGFP-Inf7, and moderate 
knockdown with unmodified siGFP. When compared to the non-targeted oligomer 188, a 
clear targeting effect was demonstrated. Sph substituted oligomers #1-2 (Figure 3.8A) 
could only mediate moderate gene silencing with siGFP-Inf7, while #3-4 (Figure 6.5) with 
one additional Sph on each arm displayed effective silencing comparable or even superior 
to 356. However, no obvious receptor targeting effect was observed. This lack of receptor 
specificity was well consistent with the analogous pDNA transfection activity. The 
elongation of the oligocationic Sph arms seems to enable nonspecific cellular attachment 
and uptake. It may be noted that a change from three Sph units (a length equivalent of >18 
aminoethane units) to four units (a length equivalent of >24 aminoethane units) results in 
an length of the oligocation arm beyond the 24 ethylene glycole units of the PEG shielding 
arm. Regarding histidine modified oligomers #5-8 (Figure 3.8B, 6.5), despite the 
enhanced buffer capacity of these oligomers, only a moderate knockdown could be 
achieved. In case of tyrosine trimers containing two-arm oligomers #9-16 (Figure 3.8C, 
6.5), the folate-targeted compounds showed improved gene silencing of up to 60% 
compared to the non-targeted oligomers, however the transfection activity remained lower 
than that of 356. The two-arm oligomers #17-20 (Figure 3.8D, 6.5), modified with both 
histidine and tyrosine trimers, exhibited the most impressive gene silencing, comparable 
to 356 and even superior at low N/P ratios. Importantly, these oligomers could also 
mediate effective silencing to the same level for both siGFP with or without endosomolytic 
siGFP-Inf7. However, in sharp contrast to 356 and also to the pDNA transfection results, 
only small differences were observed between the targeted or non-targeted oligomers 
with regard to transfection (Figure 3.8D, 6.5) and cellular uptake (see below). Apparently, 
the extension of the oligocation arms by histidines and tyrosines, together with the 
different characteristics of siRNA and pDNA polyplexes (Figure 6.1, 6.2, 3.3), are 
responsible for this difference.  
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Figure 3.8 Gene silencing in folate receptor expressing KB-eGFPLuc cells with two-arm oligomers: (A) 
oligomers without core modification; (B) oligomers modified with histidines; (C) with tyrosine trimers; (D) 
with both histidines and tyrosine trimers. The lane FolA Ligand (- or +) refers to the absence or presence of 
folate ligand within the indicated oligomer. eGFP targeted siRNA (siGFP, blue bars), control siRNA (siCtrl, 
blue bars with pattern) polyplexes and corresponding Inf7 peptide modified siRNA polyplexes (siGFP-Inf7, 
green bars, and siCtrl-Inf7, green bars with pattern) formed at N/P 6, 12 and 24 were tested for eGFPLuc 
gene silencing in KB-eGFPLuc cells. Cells were incubated with polyplexes for a short period of only 45 min, 
followed by replacement of transfection medium with fresh medium. Luciferase activities at 48 h after 
transfection are presented in percentage of relative light units (RLU) obtained with buffer treated control 
cells. The data are shown as the mean + SD (n=3). A full set of data for all oligomers is presented in Figure 
6.5. The experiment was performed by Katharina Müller (PhD student, Pharmaceutical Biotechnology, LMU 
Munich). 
 
For four-arm oligomers (Figure 3.9A, 6.5), regardless of the cationic building block, 
effective gene silencing equal to 356 or better was observed when using lytic siGFP-Inf7. 
However, also here no clear ligand dependency was detected. The oligomers #29-34 
modified with histidines (Figure 3.9B, 6.5) demonstrated a slightly reduced knockdown, 
but interestingly, oligomer #30 showed targeting efficiency compared to its negative 
control #29. The integration of tyrosine trimers into the four-arm structures led to loss of 
transfection activity (Figure 3.9C, 6.5). Similar to two-arm oligomers, four-arm oligomers 
Results 
 
 
 
39 
 
#39 and #40 modified with both histidines and tyrosine trimers (Figure 3.9D, 6.5) exhibited 
obvious knockdown even at the lowest N/P ratio of 6 and without using the lytic siGFP-
Inf7. However, this type of oligomers again demonstrated no targeting effect, since the 
knockdown was independent of the presence of a targeting ligand. 
 
Figure 3.9 Gene silencing in folate receptor expressing KB-eGFPLuc cells with four-arm oligomers: (A) four-
arm oligomers without core modification; (B) oligomers modified with histidines; (C) modified with tyrosine 
trimers; (D) modified with both histidines and tyrosine trimers. The lane FolA Ligand (- or +) refers to the 
absence or presence of folate ligand within the indicated oligomer. Polyplexes of eGFP targeted siRNA 
(siGFP, blue bars), control siRNA (siCtrl, blue bars with pattern) and corresponding Inf7 peptide modified 
siRNA (siGFP-Inf7, green bars, and siCtrl-Inf7, green bars with pattern) formed at N/P 6, 12 and 24 were 
tested for eGFPLuc gene silencing in KB-eGFPLuc cells. Cells were incubated with polyplexes for 45 min, 
followed by replacement of transfection medium by fresh medium. Luciferase activities at 48 h after 
transfection are presented as percentage of relative light units (RLU) obtained with buffer treated control 
cells. The data are shown as the mean + SD (n=3). A full set of data for all oligomers is presented in Figure 
6.5. The experiments were performed by Katharina Müller (PhD student, Pharmaceutical Biotechnology, 
LMU Munich). 
Four-arm oligomers (#39-42) with a combined modification of tyrosine trimers and 
histidines showed also a reduction of luciferase activity when transfected with siCtrl 
(Figure 3.9, 6.5), consistent with an unspecific cytotoxicity which was also observed for 
Results 
 
 
 
40 
 
the corresponding pDNA polyplexes. All other oligomers transfected with siCtrl exhibited 
no obvious reduction of luciferase activity, suggesting good biocompatibility of these 
oligomers.  
 
Figure 3.10 Cellular internalization of selected Cy5-labeled siRNA (N/P 12) polyplexes after 45 min 
determined by flow cytometry. The intensity of the Cy5 signal indicates the amount of polyplexes being 
internalized by KB-eGFPLuc cells. Light grey curve, HBG buffer only treated cells; dark grey curve, ligand 
free control oligomers treated cells; and black curve, folate containing oligomers treated cells. All 
experiments were performed in triplicate. The experiments were performed by Katharina Müller (PhD 
student, Pharmaceutical Biotechnology, LMU Munich). 
Cellular uptake studies for siRNA polyplexes formed with Cy5-labeled siRNA in folate 
receptor overexpressing KB cells are presented in Figure 3.10. As many of the folate 
containing oligomers according to the transfection results showed no targeting effect, we 
chose the most promising members #14, #18, #30 and their corresponding negative 
controls #13, #17, #29 to evaluate the uptake properties. In all of these cases folate-
targeted oligomers showed a slightly higher cellular uptake than non-targeted control 
oligomers. The high uptake of polyplexes formed with the oligomers #17 and #18 
containing both histidine and tyrosine trimers was consistent with the efficient gene 
silencing of those oligomers. 
3.2 Combinatorial polyplexes for folate receptor targeted siRNA delivery 
Successful applications of RNAi-based cancer therapy require sufficient intracellular 
delivery of siRNA to the target site and effective knockdown of targeted transcripts. Thus, 
an ideal siRNA delivery system should possess multifunctionalities to conquer multiple 
barriers all the way to its site of action[151].  Despite recent development of various 
potential siRNA carriers, systemic delivery of siRNA with specificity to the tumor site 
remains a major limitation. 
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Derived from the classic gene carrier polyethylenimine (PEI) [127] a set of artificial amino 
acids was developed comprising repeats of the 1,2-diaminoethane motif [99]. Such 
artificial oligoamino acids, like succinoyl-tetraethylene pentamine (Stp) and succinoyl-
pentaethylene hexamine (Sph) [100], in combination with natural α-amino acids, were 
applied in solid-phase assisted synthesis to generate sequence-defined cationic 
oligomers [101]. These oligomers provide excellent nucleic acid binding ability, 
endosomal buffering capacity, and site-specific positioning of multiple functionalities. 
Further studies have been undertaken to optimize such cationic carriers by systematic 
variation of the topology [103], inclusion of small chemical delivery motifs such as 
buffering histidines [23], fatty acids [102], tyrosine trimers [105], disulfide-forming units 
[106], targeting ligands [107, 109-113, 131] and combinations of such elements [152]. 
Accordingly, this strategy of a step-by-step optimization resulted in a library of >1000 
oligomers which included precise multifunctional siRNA carriers. 
Combination of two different oligomers from the library provides an alternative efficient 
option to obtain a multifunctional carrier, which may formulate therapeutic nucleic acids 
and overcome possible disadvantages of single oligomers. For example, a c-Met targeting 
PEGylated oligomer, which is deficient in DNA condensation, was combined in a 7/3 ratio 
with a 3-arm oligomer to facilitate nucleic acid compaction [110]. In our current work, we 
focused on the targeting of folate receptor (FR)-overexpressing tumors. We selected 
PEGylated folate-conjugated oligomers (for FR targeting and shielding of surface charges) 
and optimized the physicochemical properties of polyplexes by combination with a 3-arm 
oligomer (for optimizing particle size and stability) at various molar ratios. For uni-
directional fast coupling between the two types of oligomer, we activated the cysteine thiol 
groups of one of the oligomers with 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) to achieve 
a fast chemical linkage through disulfide formation with the free thiol groups of the other 
oligomer. These targeted combinatorial polyplexes (TCP) have been systemic 
investigated, regarding the particle size, zeta potential, siRNA compaction, receptor 
specific cellular uptake, and siRNA silencing in vitro and in vivo. 
3.2.1 Oligomer synthesis and formation of targeted combinatorial polyplexes 
(TCPs) 
Based on our previous studies, we selected four oligomers from the library to generate 
novel co-formulations for targeted siRNA delivery (Scheme 3.1). 3-arm Stp oligomers 386 
and 689, was chosen for their strong siRNA binding ability, which provide a highly stable 
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cationic core to compact siRNA [101, 102, 109, 153]. Moreover, PEG-folate-conjugated 
Sph oligomers (4-arm) 709 and (2-arm) 717, were used for folate receptor (FR) targeting 
and surface shielding [152]. Here we combined these two types of oligomers, in order to 
optimize the siRNA polyplexes with a co-formulation strategy. All oligomers contain 
terminal cysteines with free thiol groups for subsequent disulfide formation within siRNA 
polyplexes. As standard disulfide formation by air oxidation was previously found to be a 
rather slow and incomplete process, we intended to make this step faster and more 
specific. Therefore, we activated the thiol groups of oligomer @1 with 5,5’-dithio-bis(2-
nitrobenzoic acid) (DTNB) to produce TNB-modified oligomer (Figure 3.11A). The TNB-
modified oligomer forms binary siRNA polyplex with siRNA, and the following incubation 
with the unmodified thio-oligomer @2 will undergo a fast uni-directional coupling of TNB-
modified oligomer through disulfide formation with the free thiol groups of thio-oligomer 
@2. The combination of siRNA with both oligomers thus generates targeted combinatorial 
polyplexes (TCP), which are composed of compact cationic core for siRNA binding, well-
shielded PEG layer and folates as targeting ligands (Figure 3.11B). TCPs were optimized 
by testing different TNB-modified oligomers @1/unmodified thiol oligomers @2 at various 
molar ratios, and evaluating different siRNA and the two oligomers mixing sequences. 
Preliminary gene silencing experiments (Figure 6.6 and unpublished data) demonstrated 
similar efficiencies of the tested mixing sequences, with the first alternative (pre-incubated 
siRNA with the TNB-modified oligomer, followed by disulfide exchange reaction with thiol 
oligomer). For practical reasons, all further testing was performed with this mixing 
sequence. Four combinatorial formulations, TCP1, TCP2, TCP3 and TCP4 (Scheme 3.1), 
were developed. Both TCP1 and TCP3 contain 386 + 709 in disulfide-linked form, both 
TCP2 and TCP4 contain histidinylated 3-arm 689 + 717 PEG-folate 2-arm oligomer. 
Differences rise from the alterative TNB-activations of oligomers. After systematic 
screening and evaluating different molar ratios of oligomers (see Tables 6.2-6.5 and next 
section), equal molar (1:1) oligomer ratios and an N/P ratio of 16 was determined as most 
useful for the subsequent TCP studies.   
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Figure 3.11 Targeted combinatorial polyplexes (TCP) with folate ligand for siRNA delivery. A) TNB-modified 
oligomer @1 was obtained by reacting the solid-phase derived oligomer with 10 eq DTNB for 2 h at room 
temperature. The incubation of TNB-modified oligomer @1 with siRNA formed polyplex. Addition of thio-
oligomer resulted in fast uni-directional coupling of TNB-modified oligomer through disulfide formation with 
the free thiol groups of thio-oligomer @2. B) siRNA, TNB-modified oligomer @1 and unmodified thio-
oligomer @2 were formulated to produce TCP. Endosomolytic Inf7 peptide was conjugated to siRNA for 
enhanced endosomal escape [113]. Figure design by Dian-Jang Lee (PhD student Pharmaceutical 
Biotechnology, LMU Munich). 
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 TCP1 TCP3 
TNB 
Oligomer 
@1 
(4-arm 873) 
K-(PEG24-Folate)-K-[K-(Sph4-C-TNB)2]2 
(N/P 11.2) 
(3-arm 769) 
TNB-C-Stp3-K-(Stp3-C-TNB)2 
(N/P 4.8) 
Thiol 
Oligomer 
@2 
(3-arm 386) 
C-Stp3-K-(Stp3-C)2 
(N/P 4.8) 
(4-arm 709) 
K-(PEG24-Folate)-K-[K-(Sph4-C)2]2 
(N/P 11.2) 
 
Combined 
Structure 
 
(709-S-S-386-S-S)n 
 TCP2 TCP4 
TNB 
Oligomer 
@1 
(3-arm 770) 
TNB-C-H-(Stp-H)3-K-[(H-Stp)3-H-C-
TNB]2 
(N/P 7.4) 
(2-arm 874) 
K-(PEG24-Folate)-K-(Sph4-Y3-C-TNB)2 
(N/P 8.6) 
Thiol 
Oligomer 
@2 
(2-arm 717) 
K-(PEG24-Folate)-K-(Sph4-Y3-C)2 
(N/P 8.6)  
(3-arm 689) 
C-H-(Stp-H)3-K-[(H-Stp)3-H-C]2 
(N/P 7.4) 
 
Combined 
Structure 
 
(717-S-S-689-S-S)n 
Scheme 3.1 Targeted combinatorial polyplex (TCP) formulations. siRNA was co-formulated with TNB-
modified oligomers @1 and unmodified thiol-oligomers @2 at various molar ratios to form the TCP carriers. 
In most experiments polyplexes were formed at N/P 16 using an equal molar oligomer ratio of 1:1; for these 
conditions the individual N/P ratio of each oligomer is presented. The oligomer sequences are indicated (left 
to right) from C- to N- terminus. C: cysteine; H: histidine; K: lysine; Y: tyrosine; S-S: disulfide crosslinking; 
PEG24: polyethylene glycol; TNB: 5-thio-2-nitrobenzoic acid; Stp: succinoyl-tetraethylene pentamine; Sph: 
succinoyl-pentaethylene hexamine. K-( and K-[ refer to branchings by α- and ε-amino modification of lysines. 
Scheme design by Dian-Jang Lee (PhD student Pharmaceutical Biotechnology, LMU Munich). 
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3.2.2 Physico-chemical characteristics of TCPs 
Formulating TCPs (Scheme 3.1) at N/P 16, we measured the particle sizes by dynamic 
laser-light scattering (DLS) based on different molar ratios of [TNB-modified oligomer @1 
/ unmodified thiol-oligomer @2] (Table 6.2-6.5). At the ratio of 1:1, the sizes of the two 
386+709 formulations, TCP1 and TCP3, are 104 nm and 209 nm, respectively, whereas 
the two 689+717 formulations, TCP2 and TCP4, have a larger size of ~ 400 nm (Table 
3.3). To examine the effect of PEG shielding on the surface charge of TCPs, zeta 
potentials of siRNA polyplexes at N/P 16 were measured (Table 3.3). For TCP1, TCP2 
and TCP4, the zeta potential values were reduced from approximately ≥ +20 mV [101] to 
values around + 8-9 mV. It is interesting to see that TCP3, comprising the same oligomers 
by a different activation scheme, displays a highly positive zeta potential of +24 mV.  
ID Size (nm)  Zeta Potential (mV) 
TCP1 103.5±0.8  9.1±0.2  
TCP2 429.4±53  7.93±0.21  
TCP3 208.8±3.4  24.3±0.3  
TCP4 398.3±63.5  8.1±0.05  
Table 3.3 Size and zeta potential of TCPs at N/P 16 measured by dynamic and electrophoretic light 
scattering. [TNB-modified oligomer / unmodified thio-oligomer] molar ratio = 1:1. 
Moreover, to validate the siRNA binding activity of TCPs, we analyzed the siRNA polyplex 
formation by agarose gel shift assay (Figure 6.7-6.10). In general, when increasing the 
fraction of 3-arm Stp oligomers in TCP formulations, the siRNA binding was significantly 
increased. Apparently the 3-arm Stp oligomers were essential for the compaction and the 
stability of siRNA polyplexes. 
3.2.3 Gene silencing efficiency of TCPs 
We next evaluated their ability to induce target gene silencing. In order to validate this, 
we used siRNA targeting eGFP (siGFP) or control siRNA (siCtrl) to transfect the 
KB/eGFPLuc cells, which are stably expressing eGFP-Luciferase (eGFPLuc) fusion 
protein, and evaluated gene silencing of siRNA polyplexes via luciferase activity by 
luminometric analysis. Our previous studies indicated that PEGylated siRNA polyplexes, 
similar as several other PEG-shielded polyplexes [140], face the problem of endosomal 
entrapment into the cytosol [113]. For this reason, the synthetic peptide Inf7, previously 
designed as pH-specific analog of the influenza virus hemagglutinin subunit 2 (HA2) N-
terminal fusion sequence [29, 144, 154], was covalently coupled to siRNA as 
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endosomolytic agent [42, 113, 131]. In this assay, we sought to compare the transfection 
efficiency of TCPs with the previously published 356 [113]. As shown in Figure 3.12, all 
the TCP formulations containing Inf7-modified siGFP (siGFP-Inf7) at N/P 16 mediated 
significant gene silencing efficiency in KB/eGFPLuc cells, as 75-94% of luciferase activity 
was suppressed. Among these TCP formulations, TCP1 exhibited the most potent gene 
silencing activity (94%), which is comparable to 356 nanoplexes (90%) and superior to 
the rest of TCPs. In contrast, in the cells treated with standard siGFP polyplexes, the 
silencing effect was significantly decreased (45-63% for TCPs and 35% for 356). The 
luciferase activity in KB/eGFPLuc cells treated with controls, including siCtrl polyplexes 
and siCtrl-Inf7 polyplexes were similar to untreated cells, which suggested that there is 
no intrinsic cytotoxicity of TCPs.  
 
Figure 3.12 Gene silencing efficiency of TCPs in KB cells expressing eGFPLuc fusion protein (KB/eGFPLuc 
cells). The siRNA polyplexes were prepared at N/P 16 with different siRNA sequences: eGFP-targeted 
siRNA (siGFP), control siRNA (siCtrl), or siRNA chemically linked with the endosomolytic peptide Inf7 
(siGFP-Inf7 or siCtrl-Inf7). Statistical analysis of the results (mean ± SEM) was evaluated by unpaired t test: 
*p<0.05; **p<0.01; ***p<0.001. The experiments were performed by Dian-Jang Lee (PhD student, 
Pharmaceutical Biotechnology, LMU Munich). 
3.3 Sequence-defined branched oleoyl oligoaminoamides for nucleic acid 
delivery 
3.3.1 Synthesis of sequence-defined branched oleoyl oligoaminoamides  
Previous studies have demonstrated that solid-phase synthesis using artificial oligoamino 
acids (like Stp or Sph) as building blocks could be used to synthesis sequence defined 
cationic oligomers as carriers for nucleic acid delivery. Oligomers with different topology, 
such as linear, i-shape, T-shape, U-shape, 2-arm, 4-arm and comb structures, have been 
successfully assembled, and some of them have shown their suitability as nucleic acid 
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carriers. Previously, lipo-oligomers containing fatty acid have also been introduced as 
potential delivery vehicle for pDNA and siRNA. Here, we focused on the cationic 
counterpart of the lipo-oligomers, and investigate the influence of the different cationic 
branches on the nucleic acid compaction and gene transfer activity. For this purpose, we 
designed and synthesized a small library of lipo-oligomers with two oleic acid as the 
hydrophobic domain, while alternating the number of cationic arms with the introduction 
of lysine as the branching point. Oligomers with one, two, four and even eight cationic 
arms were assembled. To further identify the effects of the protonable amine on each arm, 
additionally, oligomers consisting of different numbers of Stp units (1 to 4) on each arm 
have been included for comparison (Scheme 3.2). Oligomers were synthesized via SPS 
start from Fmoc-Lys(ivDde)-OH loaded 2-Chlorotritylchloride resin, where lysine provides 
an asymmetrical branching point for the final attachment of oleic acid. For oligomers with 
one or two cationic arms (905-908), a resin with 0.1598 mmol/g loading was used, 
whereas for highly branched oligomers with four or eight cationic arms (909-911), a resin 
with rather low loading (=0,095 mmol/g) was used to avoid the aggregation during the 
synthesis. Terminal cysteines were integrated for polyplex stabilization via disulfide 
formation. The assembly of oligomers was finished after introducing the hydrophobic 
moiety by coupling oleic acid to an additional lysine, which was coupled to the ε-amine of 
the preloaded lysine. The sequence of all oligomers used in this study are displayed in 
Table 3.4.  
 
Scheme 3.2 Schematic structures of the synthesized lipo-oligomers. Stp, succinoyl-tetraethylene-
pentamine; K, lysine; C, cysteine; OA, oleic aicd. The light green triangle stands for the starting point of SPS. 
Results 
 
 
 
48 
 
Table 3.4 Internal library identification number (ID), sequences (from C- to N- terminus) and topology of 
synthesized lipo-oliomers. Stp, succinoyl-tetraethylene-pentamine; K, lysine; C, cysteine; OA, oleic acid. K-
(, K-[ and K-{ refer to branchings by α- and ε-amino modification of lysines. 
ID Sequence (C- to N-terminus) Topology 
905 K-(K-OA2)-Stp4-C Linear 
906 K-(K-OA2)-K-(Stp2-C)2 Two-arm 
907 K-(K-OA2)-K-(Stp3-C)2 Two-arm 
908 K-(K-OA2)-K-(Stp4-C)2 Two-arm 
909 K-(K-OA2)-K-[K-(Stp-C)2]2 Four-arm 
910 K-(K-OA2)-K-[K-(Stp2-C)2]2 Four-arm 
911 K-(K-OA2)-K-{K[K-(Stp-C)2]2}2 Eight-arm 
 
3.3.2 Biophysical poperties 
To investigate the binding behavior of these oligomers with nucleic acids (pDNA or siRNA), 
agarose gel shift assays of the formed polyplexes were performed (Figure 3.13). For 
pDNA polyplexes, all oligomers with oleoyl modification showed effective pDNA binding 
already at a low N/P of 6, independent from the cationic backbone topology. Interestingly, 
oligomer 905 with linear cationic backbone and the least number of Stp units 
demonstrated the best binding which already retained the movement of the polyplexes at 
the lowest N/P ratio. (Figure 3.13A). As for siRNA polyplexes, due to the smaller size of 
siRNA as compared to pDNA, a general lower stability for all polyplexes in the agarose 
gel shift assay has been discovered (Figure 3.13B). Again, linear oligomer 905 showed 
the best binding ability with siRNA, 2-armed oligomer showed effective binding start from 
N/P6, while for 4-armed and 8-armed oligomers, an N/P ratio of 12 or higher was required 
for stable complexation. The stability of siRNA polyplexes were further investigated with 
an additional incubation of the polyplexes with 50% FBS (37°C) at N/P12 for all oligomers. 
The gel shift assay showed these polyplexes are relative stable. 
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Figure 3.13 Gel retardation assays of pDNA (A) or siRNA (B) polyplexes formed in HBG at the indicated 
different N/P ratios. Left lanes: free pDNA or siRNA, respectively.  
Other important biophysical parameters for the evaluation of suitable polyplexes are 
particle size and zeta potential (Table 3.5). For pDNA polyplexes, particle size 
determination by dynamic laser light scattering (DLS) showed that most of the oligomers 
formed nanoparticles with a Z-average diameter between 100-140 nm and zeta potentials 
between +26 mv and +30 mV. Oligomers with more cationic branches showed a more 
compacted particles. And for oligomers within the same topology, additional Stp units 
showed a slightly higher zeta potential compared to their analogs with less cationic 
building blocks. siRNA polyplexes formed particles with a size range between 127 nm to 
170nm and zeta potentials between 26 mV to 31 mV; again a tendency towards smaller 
particle size with more branches could be discovered.  
Table 3.5 Particle size (Z-average) and zeta potential of pDNA polyplexes (N/P 12) and siRNA polyplexes 
(N/P 16) in HBG buffer measured by DLS. Polyplexes were diluted 1:20 with HEPES buffer before 
measurement. Data were presented as mean ± SD (n=3). 
Oligomer pDNA polyplexes siRNA polyplexes 
Z-average 
(nm) 
PDI Zeta potential 
(mV) 
Z-average 
(nm) 
PDI Zeta potential 
(mV) 
905 142.8±0.8 0.155±0.012 29.9±0.8 166.4±3.4 0.297±0.009 27.9±1.4 
906 130.8±1.2 0.141±0.016 27.6±3.2 149.9±2.7 0.197±0.002 30.0±1.9 
907 117.4±0.6 0.139±0.015 27.6±0.2 166.7±0.7 0.179±0.011 28.9±1.0 
908 127.7±0.6 0.153±0.009 28.4±1.6 168.1±2.3 0.268±0.011 26.8±2.3 
909 118.3±1.3 0.146±0.008 26.9±1.5 141.3±3.5 0.165±0.006 29.0±0.8 
910 115.7±0.2 0.154±0.012 28.8±0.4 135.4±2.8 0.157±0.017 30.0±1.5 
911 104.7±0.4 0.150±0.020 28.4±2.0 127.4±1.5 0.176±0.011 30.5±1.9 
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3.3.3 Biological evaluation 
The branched lipo-oligomers were used for pDNA transfection of N2A cells (Figure 3.14). 
These studies were performed by Ana Krhac Levacic (PhD student, Pharmaceutical 
Biotechnology, LMU Munich). LPEI was chosen as the positive control. Interestingly, the 
simplest structure 905 with a linear cationic backbone exhibit the highest gene transfer, 
almost to the same level as LPEI. 2-arm lipo-oligomers achieved the second place regard 
to the gene transfection efficiency, while 4-arm and 8-arm oligomers only mediate 
negligible to moderate gene transfer. In general, the gene expression level presented a 
tendency towards more branched oligomers with less gene transfer ability. For a more 
detailed comparison, oligomers with the same branched topology, those with more 
cationic Stp units, could mediate more efficient gene transfer. For example, 2-arm 
oligomers 906-908 could all mediate effective gene transfer to almost the same extinct at 
N/P 24 with an order of 908 > 907 >906. 
 
Figure 3.14 Gene transfection in Neuro2A cells with luciferase pDNA/lipo-oligomers polyplexes formed at 
N/P 3, 6, 12 or 24 (200 ng pDNA per well). LPEI polyplexes (at N/P 6) were set as the positive control. 
Luciferase activities at 24 h after transfection are presented in relative light units (RLU) as the mean + SD 
(n=5). The experiment was performed by Ana Krhac Levacic (PhD student, Pharmaceutical Biotechnology, 
LMU Munich). 
In parallel to the gene transfer studies, cell viability of Neuro2a cells were evaluated by 
an MTT assay after transfection with the pDNA polyplexes.(Figure 3.15) Importantly, all 
tested pDNA polyplexes showed no obvious toxicity. 
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Figure 3.15 Cell viability of Neuro2a cells after transfection with the pDNA polyplexes as evaluated by an 
MTT assay. pDNA/oligomer polyplexes formed at N/P 3, 6, 12 or 24 and LPEI polyplexes (at N/P 6) were 
incubated with cells for 24 h. Cell viability (%) was presented as the percentage relative to the buffer treated 
control cells. The data are shown as mean + SD (n=5). The experiments were performed by Ana Krhac 
Levacic (PhD student, Pharmaceutical Biotechnology, LMU Munich). 
 
Figure 3.16 Gene silencing in Neuro2A/eGFPLuc cells with siRNA polyplexes formed at N/P 6, 12 and 24.. 
Black bars= eGFP targeted siRNA; grey bars= control siRNA; 386 (N/P 12) was used as positive control. 
Cells were incubated with polyplexes for 48 h after initial transfection, luciferase activities are presented in 
percentage of relative light units (RLU) obtained with buffer treated control cells. The data are shown as the 
mean + SD (n=3). The experiments were performed by Katharina Müller (PhD student, Pharmaceutical 
Biotechnology, LMU Munich).  
The oligomer library was also tested for its gene silencing ability with siRNA using 
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N2a/eGFPLuc cells. Figure 3.16 presents results with the tested oligomers, 3-arm 
oligomer 386 with 9 Stp units at N/P 12 was chosen as the positive control according to 
previous studies where it shows efficient knock down. In this eGFP-luciferase gene 
silencing studies, 4-arm oligomer 909 and and 8-arm 911 which only have 1 Stp units on 
each cationic arm, showed no transfection efficiency; Oligomers 905 and 910 only 
presented slight transfection efficiency at high N/P ratios, only 2-arm oligomers 906-908 
represented moderate transfection with increasing amount of Stp per arm, and 2-arm 908 
with 4 Stp units on each arm achieved the most effective silencing at N/P 24, almost to 
the same level of the positive control 386 at N/P 12. 
3.3.4 Defined 2-arm oleoyl oligoaminoamides for folate targeted delivery 
3.3.4.1 Synthesis of defined 2-arm oleoyl oligoaminoamides with folate 
The 2-arm oligomer 908 with four Stp units on each cationic branch presented an effective 
pDNA and siRNA complexation, and also achieved the highest gene transfection among 
the branched lipo-oligomer library. Oligomer 908 contains 8 units of Stp for nucleic acid 
binding, terminal cysteine for crosslinking, and hydrophobic oleic acid for enhancement of 
polyplexes stability and uptake. In order to develop a potential carrier for targeted delivery, 
here we introduced folate as the targeting ligand and PEG24 as the shielding domain to 
the basic structure of 908, giving out a multifunctional oligomer might be suitable for pDNA 
and siRNA delivery. To identify the specific receptor mediate uptake, a negative control 
with glutamate has been introduced for comparison. Additionally, we also alternate the 
coupling position and the amount of hydrophobic oleic acid. For synthesizing the targeted 
2-arm lipo-oligomer, we started from a Dde-Lys(Fmoc)-OH loaded 2-Chlorotritylchloride 
resin where lysine provides an asymmetrical branching point, the PEG chain and folate 
was first coupled to the ε-amine of the preloaded lysine. Regarding the different coupling 
position of oleic acid, oligomer 728 and 729 was assemble by stepwise coupling of Stp 
unis, followed with cysteine and terminal lysine with two oleic acid. Alternatively, for 
oligomer 730 and 731, the synthesis was followed with the insertion of a Fmoc-Lys(Dde)-
OH where oleic acid have been coupled to the ε-amine, and finally, the assembly was 
completed with the repeated coupling of Stp units and the terminal cysteine. The exact 
structures of the targeted oligomers synthesized in this study are displayed in Scheme 
3.3. 
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Scheme 3.3 Internal liberary identification number (ID), topology and sequences (from C to N terminus) of 
PEGylated lipo-oliomers. L stands for the targeting ligand or the corresponding negative control (FolA, folic 
acid; E, glutamate); PEG, polyethylene glycol; Stp, succinoyl-tetraethylene-pentamine; K, lysine; C, cysteine; 
OA, oleic aicd. K-( and K-[ refer to branchings by α- and ε-amino modification of lysines. 
3.3.4.2 Biophysical properties 
Agarose gel shift assays were performed to investigate the compaction ability of these 
oligomers with nucleic acids (pDNA or siRNA) (Figure 3.17). For pDNA polyplexes, all 
oligomers showed almost complete compaction of pDNA binding already at the lowest 
N/P 3, independent from the position of oleic acid. For siRNA polyplexes, all oligomers 
again presented an effective compaction of siRNA started from N/P 3 and achieved 
almost complete siRNA compaction from N/P 6.  
 
Figure 3.17 Gel retardation assays of pDNA (A) or siRNA (B) polyplexes formed in HBG at the indicated 
different N/P ratios. Left lanes: free pDNA or siRNA, respectively. 
Next we investigated the particle sized and zeta potential of formed polyplexes by dynamic 
laser light scattering (DLS). (Table 3.6) Most of the pDNA polyplexes presented a Z-
ID Topology Sequence ( from C to N terminus) 
728 
 
K-(PEG24-E)-K(Stp4-C-K-OA2)2 
729 K-(PEG24-FolA)-K(Stp4-C-K-OA2)2 
730 
 
K-(PEG24-E)-K-(K-OA2)-K(Stp4-C)2 
731 K-(PEG24-FolA)-K-(K-OA2)-K(Stp4-C)2 
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average diameter between 175-265 nm and zeta potentials around +20 mV. The 
PEGylation partially shielded the polyplexes with a result of reduced zeta potential 
compared to the non-PEGylated 908 with a zeta potential of +28.4 mV. In contrast, the 
PEGylated siRNA nanoplexes are normally small and hardly measurable via DLS. 
Table 3.6 Particle size (Z-average) and zeta potential of pDNA polyplexes (N/P 12) in HBG buffer measured 
by DLS. Polyplexes were diluted 1:20 with HEPES buffer before measurement. Data were presented as 
mean ± SD (n=3). 
Oligomer  Z-average [nm] PDI Mean Zeta Potential [mV] 
728 189.1±2.8 0.492±0.037 19.5±0.2 
729 259.6±2.3 0.595±0.083 18.4±0.3 
730 263.0±4.4 0.426±0.019 22.3±0.5 
731 175.6±3.2 0.330±0.021 21.5±0.5 
 
3.3.4.3 Biological evaluation 
pDNA transfection of these oligomers have been performed in folate receptor-rich KB cells 
to evaluate their cellular specific gene transfer. (Figure 3.18). To identify the effective 
receptor-mediated uptake, the same strategy as in section 3.1.3 was performed. 
Additionally every transfection was performed with or without endolysosomotropic agent 
chloroquine, which had been previously found to facilitate endosomal escape of 
entrapped polyplexes and also contribute to the polyplexes dissociation. All oligomers 
could hardly mediate any notable gene transfer in the absence of chloroquine, with the 
help of chloroquine, moderate gene transfer could be achieved for the Folate containing 
oligomers only at the lowest N/P 3. The results suggested that endosomal escape 
represented a serious bottleneck which still had to be overcome in this delivery system. 
Taking previous findings of the enhanced pDNA compaction with increased N/P ratio, 
another possible drawbacks might be the strong binding hindered the release of the cargo. 
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Figure 3.18 Gene transfer in folate receptor expressing KB cells with selected examples of A) two-arm and 
B) four-arm oligomers. Luciferase pDNA oligomer polyplexes formed at N/P 3, 6, 12 or 24 were incubated 
with KB cells for the short period of 45 min, followed by replacement of transfection medium by fresh medium 
with (black bars) or without (grey bars) chloroquine for 4 h additional incubation before another medium 
exchange. LPEI polyplexes (at N/P 6, incubation with cells for a 4 h longer period before medium exchange) 
were set as the positive control. Luciferase activities at 24 h after transfection are presented in relative light 
units (RLU) as the mean + SD (n=5). Transfection of KB cells with pDNA polyplexes at different N/P ratios. 
The experiments were performed by Dr. Petra Kos (Pharmaceutical Biotechnology, LMU Munich). 
 
Figure 3.19 Cell viability of KB cells after transfection with the pDNA polyplexes as evaluated by an MTT 
assay. pDNA/oligomer polyplexes formed at N/P 3, 6, 12 or 24 were incubated with KB cells for 45 min, 
followed by replacement of fresh medium with (black bars) or without (grey bars) chloroquine for 4 h 
additional incubation before another medium exchange. LPEI polyplexes (at N/P 6, incubation with cells for 
4 h longer period before medium exchange) were set as the reference. Cell viabilities (%) were presented 
as the percentage relative to the buffer treated control cells. The data are shown as mean + SD (n=5). The 
experiments were performed by Dr. Petra Kos (Pharmaceutical Biotechnology, LMU Munich). 
These oligomers were also used for siRNA delivery in KB/eGFPLuc cells(Figure 3.20). 
The same transfection strategy described in section 3.1.4 was used to identify the 
receptor-mediated uptake. The lytic Inf7 peptide modified siRNA was also used to 
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enhance the endosome escape. However, none of the oligomers could mediate effective 
gene silencing, while only Inf7 modified siGFP mediated slightly better silencing efficiency. 
Another transfection approach using endolysosomotropic agent chloroquine was applied, 
and presented efficient gene silencing, while oligomer 730 and 731 with two central 
located oleic acids achieved better silencing compared to 728 and 729 with four terminal 
oleic acids. None of the siRNA polyplexes showed any receptor specific silencing. 
 
Figure 3.20 Gene silencing in folate receptor expressing KB-eGFPLuc cells. A) eGFP targeted siRNA 
(siGFP, grey bars), control siRNA (siCtrl, grey bars with dots) polyplexes and corresponding Inf7 peptide 
modified siRNA polyplexes (siGFP-Inf7, black bars, and siCtrl-Inf7, green bars with slash) formed at N/P 6, 
12 and 20 were incubated with cells for a short period of only 45 min, followed by replacement of transfection 
medium with fresh medium; B) eGFP targeted siRNA (siGFP, grey bars), control siRNA (siCtrl, black bars) 
polyplexes formed at N/P 6, 12 and 20 with additional chloroquine were incubated with cells for 4 h before 
the replacement of transfection medium with fresh medium. Luciferase activities at 48 h after transfection 
are presented in percentage of relative light units (RLU) obtained with buffer treated control cells. The data 
are shown as the mean + SD (n=3). The experiments were performed by Katharina Müller (PhD student, 
Pharmaceutical Biotechnology, LMU Munich). 
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Cellular uptake study provide further information for siRNA polyplexes (Figure 3.21). 
Folate-targeted oligomers showed a slightly higher cellular uptake than non-targeted 
control oligomers. When compared with 356, all oligomers showed an enhanced uptake. 
This might be contributed by the integration of the hydrophobic oleic acid which enhanced 
the interaction of the polyplexes by manipulating the amphiphilicity of the oligomers. 
 
Figure 3.21 Cellular internalization of selected Cy5-labeled siRNA (N/P 12) polyplexes after 45 min 
determined by flow cytometry. The intensity of the Cy5 signal indicates the amount of polyplexes being 
internalized by KB-eGFPLuc cells. Light grey curve, HBG buffer only treated cells; green curve, folate 
containing 356 polyplexes treated cells as reference;  red curve, ligand free control polyplexes treated cells; 
and blue curve, folate containing polyplexes treated cells. All experiments were performed in triplicate. The 
experiments were performed by Katharina Müller (PhD student, Pharmaceutical Biotechnology, LMU 
Munich). 
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4 Discussion 
4.1 Combinatorial optimization of sequence-defined oligo(ethanamino)amides 
for folate receptor-targeted pDNA and siRNA delivery 
For a successful nucleic acid therapy, an ideal carrier needs to overcome many different 
barriers. Thus, a multifunctional system is needed to achieve safe and efficient delivery. 
In this study, we present a combinatorial strategy to generate a library of precise oligomers 
for optimized intracellular transfer of nucleic acids. Solid-phase assisted synthesis 
enables sequence-defined incorporation of different functional domains into polymers with 
high precision.[52, 95, 96, 101] In the current work, we incorporated PEG chains for 
polyplex shielding, folate for receptor targeting, cationic two- or four-arm cores of Stp/Sph 
for nucleic acid packaging and endosomal buffering and terminal cysteines for polyplex 
stabilization by disulfide cross-linkage into oligoamino amide-based carriers. Optionally, 
as displayed in Scheme 4.1 with the detailed chemical structures of two potent carriers 
(#18 and #40), we also incorporated endosomal buffering histidines,[23, 132, 133] and 
hydrophobically stabilizing tyrosines.[105, 135] The impact of these functional domains 
on nucleic acid binding and compaction ability as well as buffer capacity of these 
oligomers, particle sizes and zeta potential values, and transfection activities of formed 
polyplexes was determined in a series of biophysical and biological tests.  
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Scheme 4.1 Chemical structures and functional microdomains of oligomers #18 and #40. Two-arm (#18) 
and four-arm (#40) oligomers as synthesized by solid-phase assisted synthesis (small blue triangles: C-
terminal linkage to solid support, start of synthesis) with folate for receptor targeting, PEG chains for 
polyplex shielding, repeated cationic Stp/Sph units for nucleic acid packaging and endosomal buffering, 
terminal cysteines for bioreducible crosslinking within polyplexes, histidines for additional endosomal 
buffering, and tyrosine trimers for hydrophobic stabilization. The functions of the individual domains are 
highlighted in color, two colors indicate a possible dual function. 
Binding behavior studies of these oligomers with nucleic acids (pDNA or siRNA) by 
agarose gel shift assays presented effective pDNA binding regardless of the cationic 
backbone, histidine and tyrosine trimer modifications of these oligomers, and less 
effective siRNA binding due to the smaller size of siRNA as compared to pDNA[147]. 
Interestingly, integration of tyrosine trimers did not promote polyplex stability. This 
contradictory observation with our previous non-PEGylated siRNA lipopolyplexes 
studies,[105] can be explained by the presence of PEG increases solubility and thus 
counteracts the hydrophobic interactions of tyrosine trimer domains. Further evaluation of 
the complexation ability by an ethidium bromide exclusion assay revealed the cationic 
charge density of the backbone as most critical point for nucleic acid interaction, with more 
cationic domains provided a better compaction, and increased insertion of domains into 
the cationic backbone decreased complexation.  
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For pDNA polyplexes, their particle size and zeta potential can be easily analyzed by 
dynamic laser light scattering (DLS), in contrast, the rather small siRNA nanoplexes were 
not measurable under this condition[131]. Although most of the oligomers formed 
nanoparticles with a Z-average diameter between 100-300 nm, some FolA conjugates 
showed larger size compared to their corresponding control oligomers, and even 
aggregation. Apparently the combination of exposed hydrophobic FolA ligands with a 
reduced electrostatic repulsion between nanoparticles causes colloidal instability and 
flocculation of polyplexes, which is consistent with other related observations.[148] 
Endosomal protonation is a key prerequisite for the transfection activity of the oligomers. 
The buffer capacity in the physiological pH range between extracellular and 
endolysosomal environment (between pH 7.4 and pH 5) for selected oligomers using 
alkalimetric back titration revealed that the incorporation of histidine domains significantly 
enhanced the buffer capacity of these oligomers, which might help in endosomal buffering, 
disruption of the endosomal membrane, and an enhanced endosomal escape through the 
hypothetical “proton sponge” effect.[21, 23, 55] 
For pDNA transfection, our previously described Stp two-arm oligomer 356 mediated 
efficient gene transfer only with the help of chloroquine, suggesting that endosomal 
escape represented a serious bottleneck which still had to be overcome. In summary, 
gene transfer activity without chloroquine was enhanced compared to the lead-structure 
356 by the incorporation of histidines and the assembly into four-arm structures with 
higher content of cationic units. The increased buffer capacity at endosomal pH and 
associated proton-sponge activity presumably is the main reason for this enhanced 
potency. For oligomers modified with tyrosine trimers, the transfection efficiency was 
mainly determined by the cationic backbone with a higher potency of the compounds 
containing the larger and better buffering Sph units.[23] Oligomers with high buffer 
capacity, such as two-arm oligomers based on Sph and four-arm oligomers, showed 
increased transfection efficiency with little or no further enhancement by chloroquine. The 
results indicate that the hydrophobic tyrosine trimers also contribute to the improved 
transfection, possibly by enhancing the interaction with lipid membranes. The highest 
transfection efficacy was achieved with the combination of histidines and tyrosine trimers 
in two-arm oligomers which by far outperformed the positive control LPEI. This class of 
best performing oligomers achieved highly efficient gene transfer in a ligand dependent 
manner, without the need for an additional external endosomal escape reagent. In 
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contrast, the transgene expression levels mediated by the analogous four-arm oligomers 
containing histidines and tyrosines dramatically decreased with increasing N/P ratio due 
to cytotoxicity. 
Table 4.1 Summary of pDNA and siRNA transfection properties. 
No. 
Gene 
transfer 
Gene 
silencing 
Dependency Receptor specificity Toxicity 
Chloro Inf7 pDNA siRNA pDNA siRNA 
356 ++ ++ ++ ++ ++ ++ - - 
#2 ++ (6) + ++ ++ ++ - - - 
#4 + (6) ++ ++ ++ - - - - 
#6 ++ + + ++ ++ - - - 
#8 +++ (6) + + ++ ++ - - - 
#10 + (24) + + - - ++ - + 
#12 + (24) + + - - ++ - - 
#14 ++ ++ + ++ ++ ++ - - 
#16 ++ + (20) - + ++ + (20) - - 
#18 +++ ++ + - ++ + - - 
#20 +++ ++ + - ++ + - + 
#22 ++ ++ + ++ ++ + - - 
#24 ++ (6) ++ + ++ ++ + - - 
#26 ++ + - ++ ++ + - - 
#28 ++ ++ + ++ + - - - 
#30 ++ (3) ++ + ++ + ++ - - 
#32 ++ (3) + + ++ + - + (12) - 
#34 ++ + - ++ ++ - - - 
#36 + (3) - - - + - + (24) - 
#38 ++ (3) - + - + - + (12) - 
#40 +++ (3) ++ + - + + + (12) + 
#42 +++ (3) ++ + + + + + (12) + 
 
The polyplex N/P ratio is 12, unless defined differently (in brackets). Gene transfer (luciferase expression): 
+, 103-105 RLU; ++, 105-107 RLU; +++, >107 RLU. Gene silencing (siGFP-Inf7 sequence specific reduction 
of marker gene expression): -, 0%-20%; +, 20%-60%; ++, 60%-100%. Dependency on chloroquine 
(Chloro): ++, transfection only with chloroquine; +, more effective with chloroquine, -, as effective without 
as with chloroquine. Dependency on Inf7: ++, transfection only with siRNA-Inf7; +, more effective with 
siRNA-Inf7; -, as effective with siRNA as with siRNA-Inf7. Receptor specificity: -, no specificity; + moderate 
specificity (negative ligand control shows lower activity); ++, specific (only FolA ligand shows transfection 
activity). Toxicity (metabolic cell activity): +, metabolic activity ≤  80%; -, metabolic cell activity > 
80%.Summary prepared by Katharina Müller and Ana Krhac Levacic (PhD students, Pharmaceutical 
Biotechnology, LMU Munich). 
For siRNA mediated gene silencing (Table 4.1), the use of endosomolytic Inf7-siRNA 
demonstrated a clear advantage for transfections. Oligomers with increased number of 
cationic building blocks or polycationic arms generally demonstrated enhanced silencing 
efficiency due to their enhanced compaction ability (compare Figure 6.2 and 3.3). 
Oligomers modified with only histidines or tyrosine trimers, exhibited slightly reduced 
knock down, despite the enhanced buffer capacity and membrane interaction. A possible 
explanation might be the decreased siRNA binding ability demonstrated by gel shift as 
well as ethidium bromide assay. For some of these oligomers, a modest targeting effect 
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could be observed in the transfection results. Similar to pDNA transfection, the combined 
integration of histidines and tyrosine trimers into two-arm structures turned out to be the 
most effective combination. Highly effective gene silencing could be achieved without 
coupling endosomolytic Inf7 peptide to the siRNA. 
Cytotoxicity of the cationic oligomers is another major concerns for the use as nucleic acid 
carriers. MTT assay after transfection with the pDNA polyplexes revealed only the four-
arm oligomers containing tyrosine trimers showed obvious toxicity at higher N/P ratios.  
Four-arm oligomers (#39-42) with a combined modification of tyrosine trimers and 
histidines also presented a reduction of luciferase activity when transfected with siCtrl 
polyplexes. Presumably, the increased hydrophobicity caused by the higher number of 
tyrosines in four-arm oligomers led to increased cytotoxicity. All other oligomers 
transfected with siCtrl exhibited no obvious reduction of luciferase activity, suggesting 
good biocompatibility of these oligomers.  
Cellular uptake studies was performed to identify the receptor mediated uptake properties. 
For pDNA polyplexes, targeted polyplexes presented beneficial uptake which was 
consistent with the transfection data and confirmed the targeting effect. While for siRNA 
polyplexes, only a slightly higher cellular uptake than non-targeted control oligomers 
coulbe be observed. 
The empirical finding that the same compound class turned out to be most effective pDNA 
and siRNA carriers was surprising, considering the different demands on pDNA and 
siRNA delivery, such as different biophysical polyplex stabilities and biological target site 
(i.e. cytosolic versus nuclear site of action). We conclude that critical early, shared steps 
of the delivery process, including polyplex stabilization, endocytosis and endosomal 
release were dominating the selection of favorable functional domains. Nevertheless, 
closer inspection revealed subtle differences; siRNA polyplexes displayed diminished 
receptor-specificity and ligand-dependency than pDNA polyplexes, consistent with their 
reduced polyplex stability and compaction (Figure 6.1, 6.2, and 3.3). In sum, the 
systematic screen of forty-two PEG-containing oligomers provided interesting structure-
activity relations and identified oligomers with strongly improved nucleic acid transfection 
profile in vitro. It will be interesting to see their performance in future in vivo studies. 
4.2 Combinatorial polyplexes for folate receptor targeted siRNA delivery  
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An ideal siRNA delivery system should possess multifunctionalities to conquer multiple 
barriers all the way to its site of action. Beside the step-by-step optimization strategy we 
discussed in the first part, here we developed an approach via combination of two different 
oligomers from the library to obtain a multifunctional carrier for siRNA delivery. In the 
current work, PEGylated folate-conjugated oligomers for folate receptor (FR) targeting 
and surface shielding, and 3-arm oligomers for siRNA binding and polyplexes stabilizing 
have been chosen to generate novel co-formulations for targeted siRNA delivery. By 
activation of the cysteine thiol groups of one of the oligomers with 5,5’-dithio-bis(2-
nitrobenzoic acid) (DTNB), uni-directional fast coupling between the two types of oligomer 
could be achieved by a fast disulfide formation with the free thiol groups of the other 
oligomer. In combination with siRNA, TCPs have been generated with various mixing ratio 
of the two oligomers and the mixing sequence of siRNA with the two oligomers. The 
formation sequence of TCPs by first mixing of TNB modified oligomers with siRNA, 
followed with the adding of unmodified thiol-oligomers have been chosen for further 
studies. Generally, by alternating the TNB-modification of oligomers, four TCPs were 
developed and evaluated for their biophysico-chemical properties, and in vitro siRNA 
silencing properties.  
DLS has been used to measure the particle sizes and zeta potential of TCPs based on 
different molar ratios of TNB-modified oligomer and unmodified thiol-oligomer. TCPs 
presented different particle sizes, despite their identical final consistent oligomers, such 
as TCP1 and TCP3, TCP2 and TCP4. Reduced surface charges, except TCP3, could be 
observed with the adding of PEGylated component. The results suggested the particle 
size and zeta potential could be influenced by the alternative TNB-activated oligomers. 
Agarose gel shift assay revealed that, non-PEGylated 3-arm oligomers were essential for 
the compaction of siRNA to form stable polyplexes, and the TCPs showed superior 
compaction of siRNA.  
siRNA silencing studies showed all the TCP formulations containing Inf7-modified siGFP 
(siGFP-Inf7) at N/P 16 mediated significant gene silencing efficiency in KB/eGFPLuc cells, 
identified TCP1 as the most potent formulation, and further highlighted the benefice of 
using Inf7 modified siRNA for siRNA transfection. Furthermore, the adequate luciferase 
activity of siCtrl treated cells compare to the untreated cells suggested the high 
biocompatibility of TCPs. 
These targeted combinatorial polyplexes (TCP) with favorable particle size and surface 
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charge showed significant tumor cell-specific eGFP-luciferase marker gene silencing 
without cytotoxicity in vitro. The in vitro EG5 gene knockdown ability, FR-mediated 
internalization by flow cytometry and immuno-TEM, and also in vivo studies, will be 
discussed in Dian-Jang Lee’s thesis (PhD student, LMU Munich). Remarkably, after 
intravenous administration in tumor-bearing mice, the most promising TCP1 generated 
with a 3-arm Stp oligomer and a TNB-modified 4-arm PEGylated targeted Sph oligomer 
exhibited siRNA delivery into the tumor and resulted in in vivo EG5 gene silencing in the 
tumor as demonstrated at mRNA level. 
4.3 Sequence-defined branched oleoyl oligoaminoamides for nucleic acid 
delivery 
In the present work, solid-phase synthesis in combination with artificial oligoamino acids 
(like Stp or Sph), natural amino acids and oleic acid as building blocks were applied to 
assemble branched sequence defined oleoyl oligoaminoamides as carriers for nucleic acid 
delivery. To investigate whether the different cationic branches of the oligomer can 
influence the gene transfection, a small library of lipo-oligomers with two oleic acid as the 
hydrophobic domain and different cationic branches was synthesized and investigated. 
Oligomers consisting of different Stp units on each arm have been included to further 
address the effects of the protonable amines on each arm. Terminal cysteines were 
integrated for polyplex stabilization via disulfide formation. 
Nucleic acids (pDNA or siRNA) complexation studies using agarose gel shift assays 
showed linear oligomer the best binding ability for both pDNA and siRNA, effective pDNA 
binding start from N/P 6 for all oligomers independent from the cationic backbone topology, 
and less siRNA binding with increased branches. This polyplex formation can be 
attributed to multivalent electrostatic interactions between the negatively charged nucleic 
acid with oligomers, therefore, oligomers with the same amount of Stp units which 
contribute to the positive charge of the oligomer showed a reduced charge density with 
increased branches. Similarly, oligomers of the same topology with additional Stp units 
present a higher charge density and leads to a better complexation. 
Particle size determined by dynamic laser light scattering (DLS) showed a tendency 
towards smaller particle size with more branches oligomers for both pDNA and siRNA 
polyplexes. One possible reason is that the increasing amount of cysteine corresponding 
to increasing branches affects the particle size through additional disulfide crosslinking 
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resulting in a more compact structure. Compare to a previous study by Klein et al.[106] 
where more cysteines as CRC motifs integrated into the 3-arm structure resulted in 
smaller particle size of the formed polyplexes. And generally, pDNA polyplexes presented 
smaller particle size compared to the siRNA polyplexes. This might be resulted in the 
smaller size of siRNA which leads to a looser compaction. 
pDNA transfection studies presented a tendency towards less gene transfer ability with 
more branched oligomers. While for siRNA silencing, almost the same phenomenon was 
discovered, only the liner oligomer showed no effective silencing. For a more detailed 
comparison of oligomers with the same branched topology, those with more cationic Stp 
units could mediate more efficient gene transfer. Generally, more protonatable amines 
per arm mean an overall increased charge density. This leads to not only the enhanced 
nucleic acid compaction, but also enhanced interaction with the negative charged cell 
surface, which is beneficial for non-specific uptake. And furthermore, more Stp units 
provide an increased buffer capacity with the remaining not protonated amines. This 
explains the low transfection of the linear oligomer. Since cytotoxicity remains one of the 
major issue for developing suitable gene carriers, both MTT assay and the high eGFP-
Luc expression level of control siRNA transfected cell indicated the all the oligomers 
possess a favorable biocompatibility as nucleic acid carrier. 
As the 2-arm oligomer 908 with four Stp units on each cationic branch presented an 
effective pDNA and siRNA complexation, and also achieved the highest gene transfection 
among the branched lipo-oligomer library, it was selected as the basic structure for further 
modification with the introduction of folate as the targeting ligand and PEG24 as the 
shielding domain, with the purpose to develop a multifunctional oligomer for targeted 
pDNA and siRNA delivery. Negative control ligand glutamate was introduced to address 
the specific receptor mediate uptake. Additionally, we also alternate the coupling position 
and the amount of hydrophobic oleic acid to identify the influence of the hydrophobic 
moiety. 
Agarose gel shift assays identified all oligomers showed an effective compaction, and 
almost complete compaction of pDNA and siRNA start form N/P 3 and 6 respectively. A 
general slightly enhanced binding ability of oligomers was demonstrated compared to 
their basic structure 908 which does not have PEG modification. The zeta potential of 
polyplexes formed with the targeted PEGylated oligomers presented lower value 
compared to that of non-PEGylated 908, demonstrating the partial shielding of polyplexes, 
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which would be beneficial for in vivo studies, to avoid unspecific interactions with serum 
proteins. 
As for the pDNA transfection of these oligomers, a moderate gene transfer was observed 
only at the lowest N/P 3, and only with the presence of endolysosomotropic chloroquine, 
which had been previously found to facilitate endosomal escape of entrapped polyplexes 
and also contribute to the polyplex dissociation [23, 109]. For siRNA transfection studies, 
again chloroquine was shown to be crucial for efficient gene silencing. Including the 
cellular uptake study of an enhanced uptake compare to the oligomer 356 siRNA 
polyplexes without lipid, the delivery pathway might be caught in the endosomal escape 
and the following cargo release. The results suggested that endosomal escape 
represented a serious bottleneck which still had to be overcome in this delivery system. 
Taking previous findings of the enhanced pDNA compaction with increased N/P ratio, 
another possible drawback might be the strong binding hindered the release of the cargo. 
This would be consistent with siRNA polyplex transfections with lytic Inf7 modified siRNA, 
which have been proved to be beneficial for siRNA transfection with enhance endosomal 
escape, but only achieved slightly silencing effects. The interaction of the Inf7 peptide with 
the lipid moiety may strengthen the compaction and might also contribute for its loss of 
function. Another issue is the PEG chain, which has 24 ethylene glycol units compared to 
24 protonable ethylenimine units of the oligomer, the endosomal escape process might 
be hindered. 
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5 Summary 
Over the past twenty years, nucleic acid based therapy represents as a promising future 
treatment option for life threatening diseases caused by genetic defects, such as inherited 
single gene disorders, cancer and so on. However, the development of nucleic acid 
therapy has been caught in the development of efficient and safe delivery systems. 
Generally, the nucleic acid carrier needs to be multifunctional to conquer the multiple 
barriers all the way to its action site. In this thesis, based on the recent developed solid-
phase synthesis platform with artificial polyamino acids, we focused on the development 
of sequence-defined multifunctional oligomers for nucleic acid delivery. With different 
aims, two strategies to optimize the targeted nucleic acid delivery system have been 
presented, and additional investigation on the influence of cationic branching units have 
been discussed. 
In the first part, the stepwise optimization of oligomers for nucleic acid delivery was carried 
out by SPS. A library of forty-two sequence-defined oligomers comprising the artificial 
polyamino acids for nucleic acid complexation, monodisperse polyethylene glycol (PEG) 
for surface shielding, and folic acid for receptor-specific cellular uptake, with systemic 
variations of (1) the type of artificial oligoamino acid building block (Stp or Sph), (2) the 
topology (two-arm or four-arm), (3) additional histidines for enhanced endosomal pH-
buffering and/or (4) terminal tyrosine trimers for enhanced stability of the formed 
polyplexes, have been synthesized and systematically evaluated for properties in pDNA 
and siRNA delivery. The resulting structure activity relationships identified different 
beneficial modules for the delivery of pDNA and siRNA, and oligomers with strongly 
improved nucleic acid transfection profile in vitro. Two-arm oligomers modified with a 
combination of histidines and tyrosine trimers achieved the most effective transfection of 
pDNA and siRNA. It will be interesting to see their performance in future in vivo studies. 
In the second part, a combinatorial optimization strategy have been utilized to develop 
multifunctional folate-bearing targeted combined polyplexes (TCPs) for FR-directed 
siRNA delivery, this was achieved by reacting a TNB-modified oligomer with a thiol-
containing oligomer and formulation with siRNA. The TCPs were spherical homogenous 
particles, with effective siRNA compaction ability and PEG-shielded nanoparticle surface. 
These TCPs showed significant tumor cell-specific eGFP-luciferase marker gene 
silencing without cytotoxicity in vitro, and identified TCP1 generated with a 3-arm Stp 
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oligomer and a TNB-modified 4-arm PEGylated targeted Sph oligomer as the most potent 
formulation. Further development of TCPs with siEG5 as therapeutic TCPs for tumor 
reveals TCPs as great potential for a safe and effective delivery system for RNAi-based 
cancer therapy. 
In the third part, SPS has been applied to assemble branched sequence defined oleoyl 
oligoaminoamides as carriers for nucleic acid delivery. Special focus was put on the 
influence of different cationic branches of the oligomer on the nucleic acid compaction 
and gene transfer activity. A library of lipo-oligomers with two oleic acid as the hydrophobic 
domain and terminal cysteines for polyplex stabilization, while alternating the number of 
cationic arms (one, two, four, eight) and the number of Stp units (1 to 4) on each arm have 
been synthesized and investigated. The 2-arm oligomer 908 with four Stp units on each 
cationic branch presented an effective pDNA and siRNA complexation, and also achieved 
the highest gene transfection among the branched lipo-oligomer library. A further attempt 
to generate targeted lipo-oligomers by introducing folate as the targeting ligand and 
PEG24 as the shielding domain to the 908, leads to inefficient transfection which might 
be caught in the endosome escape and/or cargo release pathway. 
In summary, this doctoral study focused on the optimization of polyplexes for nucleic acid 
delivery based on the SPS platform. The structure activity relationship of sequence 
defined targeted oligomers, the achievement of targeted combinatorial polyplexes, and 
the up to now unsuccessful targeted lipo-oligomers, all provide interesting and useful 
information for future optimization of synthetic carriers for nucleic acid delivery. 
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6 Appendix 
6.1 Abbreviations 
ACN Acetonitrile 
Boc tert-Butoxycarbonyl 
c-Met Hepatocyte growth factor receptor 
CMV Cytomegalovirus 
Cy5 Cyanine 5 
D2O Deuterium oxide 
DAPI 4',6-Diamidino-2-phenylindole 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM Dichloromethane 
Dde 1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-ethyl 
DIPEA N,N-Diisopropylethylamine 
DLS Dynamic laser-light scattering 
DMEM Dulbecco’s modified Eagle’s medium 
DMF N,N-Dimethylformamide 
DMSO Dimethylsulfoxide 
DNA  Desoxyribonucleic acid 
DODT 3,6-Dioxa-1,8-octanedithiol 
DPL Poly(L-lysine) dendrimer 
dsRNA Double-stranded RNA 
DTNB 5,5’-Dithio-bis(2-nitrobenzoic acid) 
EDTA Ethylendiaminetetraacetic acid 
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EtBr Ethidium bromide 
FBS Fetal bovine serum 
Fmoc Fluorenylmethoxycarbonyl 
FolA Folic acid 
FR Folate receptor 
Gtp Glutaryl-tetraethylene pentamine 
Gtt Glutaryl-triethylene tetramine 
HBG HEPES buffered glucose 
HCl Hydrochloric acid 
HEPES N-(2-hydroxethyl) piperazine-N‘-(2-ethansulfonic acid) 
HOBt 1-Hydroxybenzotriazole 
ivDde 1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl 
KCN Potassium cyanide 
LPEI Linear polyethylenimine 
miRNA MicroRNA 
mRNA Messenger RNA 
MTBE Methyl tert-butyl ether 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
N/P ratio Nitrogen/phosphate ratio 
NaOH Sodium hydroxide 
NMR Nuclear magnetic resonance 
PAA Polyamino acid 
PAMAM Poly(amidoamine) dendrimer 
PBS Phosphate buffered saline 
pCMVLuc Plasmid encoding firefly luciferase under the control of the CMV promoter 
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PDI Polydispersity index 
pDNA Plasmid DNA 
PEG Polyethylene glycol 
PEHA Pentaethylene hexamine 
PPI Polypropylenimine 
Poly(I:C) Polyinosinic polycytidylic acid 
PyBOP Benzotriazol-1-yloxy-tripyrrolidinophosphonium hexafluorophosphate 
RLU Relative light units 
RP-HPLC Reversed-phase high performance liquid chromatography 
RPMI Roswell Park Memorial Institute medium 
RT Room temperature 
SEC Size-exclusion chromatography 
siRNA Small interfering RNA 
Sph Succinoyl-pentaethylene hexamine 
SPS Solid-phase synthesis 
Stp Succinoyl-tetraethylene pentamine 
TBE Tris-boric acid-EDTA buffer 
TCEP Tris(2-carboxyethyl)phosphine 
TEPA Tetraethylene pentamine 
TEM Transmission electron microscopy 
TFA Trifluoroacetic acid 
TIS Triisopropylsilane 
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6.2 Supporting figures and tables 
Table 6.1 Overview of the synthesized PEGylated oligomers, their numbers in the manuscript, internal 
library compound IDs, and sequences (left to right: from C- to N-terminus). 
No. ID Sequence (C to N terminus) 
356 356 C-Stp4-K-(PEG24-FolA)-Stp4-C 
#1 690 K-(PEG24-Acetate)-K-(Sph3-C)2 
#2 691 K-(PEG24-FolA)-K-(Sph3-C)2 
#3 692 K-(PEG24-Acetate)-K-(Sph4-C)2 
#4 693 K-(PEG24-FolA)-K-(Sph4-C)2 
#5 788 K-(PEG24-E)-K-[(H-Stp)3-H-C]2 
#6 789 K-(PEG24-FolA)-K-[(H-Stp)3-H-C]2 
#7 790 K-(PEG24-E)-K-[(H-Stp)4-H-C]2 
#8 791 K-(PEG24-FolA)-K-[(H-Stp)4-H-C]2 
#9 879 K-(PEG24-E)-K-(Stp3-Y3-C)2 
#10 880 K-(PEG24-FolA)-K-(Stp3-Y3-C)2 
#11 881 K-(PEG24-E)-K-(Stp4-Y3-C)2 
#12 882 K-(PEG24-FolA)-K-(Stp4-Y3-C)2 
#13 714 K-(PEG24-E)-K-(Sph3-Y3-C)2 
#14 715 K-(PEG24-FolA)-K-(Sph3-Y3-C)2 
#15 716 K-(PEG24-E)-K-(Sph4-Y3-C)2 
#16 717 K-(PEG24-FolA)-K-(Sph4-Y3-C)2 
#17 792 K-(PEG24-E)-K-[(H-Stp)3-H-Y3-C]2 
#18 793 K-(PEG24-FolA)-K-[(H-Stp)3-H-Y3-C]2  
#19 794 K-(PEG24-E)-K-[(H-Stp)4-H-Y3-C]2 
#20 795 K-(PEG24-FolA)-K-[(H-Stp)4-H-Y3-C]2  
#21 732 K-(PEG24-E)-K-[K-(Stp3-C)2]2 
#22 733 K-(PEG24-FolA)-K-[K-(Stp3-C)2]2 
#23 734 K-(PEG24-E)-K-[K-(Stp4-C)2]2 
#24 735 K-(PEG24-FolA)-K-[K-(Stp4-C)2]2 
#25 706 K-(PEG24-A)-K-[K-(Sph3-C)2]2 
#26 707 K-(PEG24-FolA)-K-[K-(Sph3-C)2]2 
#27 708 K-(PEG24-A)-K-[K-(Sph4-C)2]2 
#28 709 K-(PEG24-FolA)-K-[K-(Sph4-C)2]2 
#29 761 K-(PEG24-E)-K-[H-K-((H-Stp)3-H-C)2]2 
#30 762 K-(PEG24-FolA)-K-[H-K-((H-Stp)3-H-C)2]2 
#31 763 K-(PEG24-E)-K-[H-K-((H-Stp)4-H-C)2]2 
#32 764 K-(PEG24-FolA)-K-[H-K-((H-Stp)4-H-C)2]2 
#33 712 K-(PEG24-E)-K-[H-K-((H-Sph)3-H-C)2]2 
#34 713 K-(PEG24-FolA)-K-[H-K-((H-Sph)3-H-C)2]2 
#35 875 K-(PEG24-E)-K-[K-(Stp3-Y3-C)2]2 
#36 876 K-(PEG24-FolA)-K-[K-(Stp3-Y3-C)2]2 
#37 877 K-(PEG24-E)-K-[K-(Stp4-Y3-C)2]2 
#38 878 K-(PEG24-FolA)-K-[K-(Stp4-Y3-C)2]2 
#39 765 K-(PEG24-E)-K-[H-K-((H-Stp)3-H-Y3-C)2]2 
#40 766 K-(PEG24-FolA)-K-[H-K-((H-Stp)3-H-Y3-C)2]2 
#41 767 K-(PEG24-E)-K-[H-K-((H-Stp)4-H-Y3-C)2]2 
#42 768 K-(PEG24-FolA)-K-[H-K-((H-Stp)4-H-Y3-C)2]2 
FolA, folic acid as targeting ligand; A, alanine; E, glutamate; or acetate as corresponding ligand controls; 
Stp, succinoyl-tetraethylene-pentamine; Sph, succinoyl-pentaethylene-hexamine; PEG, polyethylene glycol; 
K, lysine; H, histidine; Y, tyrosine; and C, cysteine. K-[ and K-( refer to branching by α- and ε-amino 
modification. 
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Figure 6.1. Gel retardation assays of pDNA polyplexes formed with oligomers at different indicated N/P 
ratios in HBG. Left lane: free pDNA. 
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Figure 6.2 Gel retardation assays of siRNA polyplexes formed with oligomers at different indicated N/P 
ratios in HBG. Left lane: free siRNA. 
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Figure 6.3. Luciferase pDNA transfection in folate receptor expressing KB cells with synthesized oligomers. 
Luciferase polyplexes were formed at the indicated N/P ratios of 3, 6, 12 or 24 and incubated with KB cells 
(200ng pCMVLuc per well) for the short period of 45 min in folate-free serum-supplemented medium, 
followed by replacement of transfection medium by fresh medium with (black bars) or without (grey bars) 
chloroquine. LPEI polyplexes (at N/P 6, incubation with cells for a longer 4 h period before medium 
exchange) were set as the positive control, HBG buffer served as negative control. Luciferase activities at 
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24 h after transfection are presented in relative light units (RLU) as the mean + SD (n= 5). The experiments 
were performed by Ana Krhac Levacic and Dr. Petra Kos (Pharmaceutical Biotechnology, LMU Munich). 
 
Figure 6.4 Metabolic activities of KB cells after transfection with the pDNA polyplexes as evaluated by an 
MTT assay. pDNA/oligomer polyplexes formed at N/P 3, 6, 12 or 24 were incubated with KB cells for 45 
min, followed by replacement of fresh medium with (black bars) or without (grey bars) chloroquine for 4h 
additional incubation before medium exchange. LPEI polyplexes (at N/P 6, incubation with cells for 4 h 
period before medium exchange) were set as the reference. Metabolic activities (%) were presented as 
the percentage relative to the buffer treated control wells. The data are shown as mean + SD (n=5). The 
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experiments were performed by Ana Krhac Levacic and Dr. Petra Kos (Pharmaceutical Biotechnology, 
LMU Munich). 
 
Figure 6.5 Gene silencing in folate receptor expressing KB-eGFPLuc cells with two-arm oligomers: (A) 
two-arm oligomers without core modification; (B) oligomers modified with histidines; (C) with tyrosine 
trimers; (D) with both histidines and tyrosine trimers. The lane FolA Ligand (- or +) refers to the absence 
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or presence of folate ligand within the indicated oligomer. eGFP targeted siRNA (siGFP, blue bars), control 
siRNA (siCtrl, blue bars with dots) polyplexes and corresponding Inf7 peptide modified eGFP targeted 
(siGFP-Inf7, green bars) and control (siCtrl-Inf7, green bars with dots) siRNA polyplexes formed at N/P 6, 
12 and 20 or 24 for eGFPLuc gene silencing were incubated with KB-eGFPLuc cells for 45 min, followed 
by replacement of transfection medium by fresh medium. Luciferase activities at 48 h after transfection are 
presented in percentage of relative light units (RLU) obtained with buffer treated control cells. The data are 
shown as the mean + SD (n=3).  The experiment was performed by Katharina Müller (PhD student, 
Pharmaceutical Biotechnology, LMU Munich). 
 
Table 6.2 Size (by dynamic light scattering) and zeta potential of TCP1 at N/P 16. K-(PEG24-Folate)-K-[K-
(Sph4-C-TNB)2]2 (873) as TNB-modified oligomer and C-Stp3-K-(Stp3-C)2 (386) as unmodified oligomer 
were co-formulated according to different molar ratios to form siRNA polyplexes for size assessments. n.d. 
= not detectable. 
 
[TNB-Modified Oligomer / 
Unmodified Oligomer]  
Molar Ratio 
Individual N/P Ratios 
Size (nm) 
Zeta 
Potential 
(mV) TNB-Modified 
Oligomer 
Unmodified 
Oligomer 
TNB-
Modified 
Oligomer 
Unmodified 
Oligomer 
100% - 16 0 n.d. n.d. 
80% 20% 14.5 1.5 n.d. n.d. 
60% 40% 12.5 3.5 98.2±9.4 14.7±1.5 
50% 50% 11.2 4.8 103.5±0.8 9.1±0.2 
40% 60% 9.8 6.2 71.3±20 11.9±0.4 
20% 80% 5.9 10.1 129.8±31 11.5±0.9 
- 100% 0 16 883.7±80.2 24.1±0.9 
 
 
 
Table 6.3 Size (by dynamic light scattering) and zeta potential of TCP2 at N/P 16. TNB-C-H-(Stp-H)3-K-
[(H-Stp)3-H-C-TNB]2 (770) as TNB-modified oligomer and K-(PEG24-Folate)-K-(Sph4-Y3-C)2 (717) as 
unmodified oligomer were co-formulated according to different molar ratios to form siRNA polyplexes for 
size assessments. n.d. = not detectable. 
 
[TNB-Modified Oligomer / 
Unmodified Oligomer]  
Molar Ratio 
Individual N/P Ratios 
Size (nm) 
Zeta 
Potential 
(mV) TNB-Modified 
Oligomer 
Unmodified 
Oligomer 
TNB-Modified 
Oligomer 
Unmodified 
Oligomer 
100% - 16 0 289.3±43.62 14.3±0.1 
80% 20% 12.4 3.6 512.8±39.39 7.90±0.146 
60% 40% 9.0 7.0 473.5±45.8 7.79±0.1 
50% 50% 7.4 8.6 429.4±52.54  7.93±0.2 
40% 60% 5.8 10.2 448.8±15.27 11.4±0.52 
20% 80% 2.8 13.2 569.9±27.36  12.3±0.115 
- 100% 0 16 n.d. n.d. 
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Table 6.4 Size (by dynamic light scattering) and zeta potential of TCP3 at N/P 16. TNB-C-Stp3-K-(Stp3-C-
TNB)2 (769) as TNB-modified oligomer and K-(PEG24-Folate)-K-[K-(Sph4-C)2]2 (709) as unmodified 
oligomer were co-formulated according to different molar ratios to form siRNA polyplexes for size 
assessments.n.d. = not detectable. 
 
[TNB-Modified Oligomer / 
Unmodified Oligomer]  
Molar Ratio 
Individual N/P Ratios 
Size (nm) 
Zeta 
Potential 
(mV) TNB-Modified 
Oligomer 
Unmodified 
Oligomer 
TNB-Modified 
Oligomer 
Unmodified 
Oligomer 
100% - 16 0 266.3±7.4 17.9±0.1 
80% 20% 10.1 5.9 159.8±5.4 23.2±0.4 
60% 40% 6.2 9.8 195.5±3.2. 27.5±1.3 
50% 50% 4.8 11.2 208.8±3.4 24.3±0.3 
40% 60% 3.5 12.5 n.d. n.d. 
20% 80% 1.5 14.5 n.d. n.d. 
- 100% 0 16 n.d. n.d. 
 
 
 
Table 6.5 Size (by dynamic light scattering) and zeta potential of TCP4 at N/P 16. K-(PEG24-Folate)-K-
(Sph4-Y3-C-TNB)2 (874) as TNB-modified oligomer and C-H-(Stp-H)3-K-[(H-Stp)3-H-C]2 (689) as 
unmodified oligomer were co-formulated according to different molar ratios to form siRNA polyplexes for 
size assessments. n.d. = not detectable. 
 
[TNB-Modified Oligomer / 
Unmodified Oligomer]  
Molar Ratio 
Individual N/P Ratios 
Size (nm) 
Zeta 
Potential 
(mV) TNB-Modified 
Oligomer 
Unmodified 
Oligomer 
TNB-Modified 
Oligomer 
Unmodified 
Oligomer 
100% - 16 0 454.4±72.3 5.3±0.4 
80% 20% 13.2 2.8 332.3±67.2 8.2±0.3 
60% 40% 10.2 5.8 442.7±105.7 7.8±0.2 
50% 50% 8.6 7.4 398.3±63.5 8.1±0.5 
40% 60% 7.0 9.0 445.2±62.7 8.6±0.2 
20% 80% 3.6 12.4 393.3±48.7 10.1±0.2 
- 100% 0 16 139.3±4.9 14.9±1.2 
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Figure 6.6 Gene silencing efficiency of TCP1 in KB/eGFPLuc cells using different alternative mixing 
sequences. The siRNA polyplexes were prepared at N/P 16 with 370 nM different siRNA sequences: 
eGFP-targeted siRNA (siGFP), control siRNA (siCtrl), or siRNA chemically linked with the endosomolytic 
peptide Inf7 (siGFP-Inf7 or siCtrl-Inf7). The different mixing sequences were compared: Alternative 1), also 
used for the majority of experiments; the TNB-modified oligomer solution was pre-incubated with siRNA 
solution for 30 min, then was incubated with unmodified oligomer solution for 40 min. Alternative 2) The 
TNB-modified oligomer solution and unmodified oligomer solution were incubated all together with siRNA 
solution for 40 min. Alternative 3) Unmodified oligomer solution was pre-incubated with siRNA solution for 
30 min, then further incubated with TNB-modified oligomer solution for 40 min. The experiments were 
performed by Dian-Jang Lee (PhD student, Pharmaceutical Biotechnology, LMU Munich). 
 
 
Figure 6.7 siRNA binding of TCP1 determined by agarose gel shift assay. K-(PEG24-Folate)-K-[K-(Sph4-
C-TNB)2]2 (873) as TNB-modified oligomer and C-Stp3-K-(Stp3-C)2 (386) as unmodified oligomer were co-
formulated according to different molar ratios to form siRNA polyplexes at N/P 3, 6, 12 and 24. Free siRNA 
was used as control. 
 
 
Figure 6.8 siRNA binding of TCP2 determined by agarose gel shift assay. TNB-C-H-(Stp-H)3-K-[(H-Stp)3-
H-C-TNB]2 (770) as DTNB-modified oligomer and K-(PEG24-Folate)-K-(Sph4-Y3-C)2 (717) as unmodified 
oligomer were co-formulated according to different molar ratios to form siRNA polyplexes at N/P 3, 6, 12 
and 24. Free siRNA was used as control. 
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Figure 6.9 siRNA binding of TCP3 determined by agarose gel shift assay. TNB-C-Stp3-K-(Stp3-C-TNB)2 
(769) as DTNB-modified oligomer and K-(PEG24-Folate)-K-[K-(Sph4-C)2]2 (709) as unmodified oligomer 
were co-formulated according to different molar ratios to form siRNA polyplexes at N/P 3, 6, 12 and 24. 
Free siRNA was used as control. 
 
 
Figure 6.10 siRNA binding of TCP4 determined by agarose gel shift assay. K-(PEG24-Folate)-K-(Sph4-Y3-
C-TNB)2 (874) as DTNB-modified oligomer and C-H-(Stp-H)3-K-[(H-Stp)3-H-C]2 (689) as unmodified 
oligomer were co-formulated according to different molar ratios to form siRNA polyplexes at N/P 3, 6, 12 
and 24. Free siRNA was used as control. 
 
6.3 Analytical data 
1H-NMR Data of Oligomers 
#1(690): K-(PEG24-Acetate)-K-(Sph3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 1.97 (s, 3H, acetate 
CH3), 2.4-2.7 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 3.0-3.6 (m, 128 H, -CH2- 
Tp, εH lysine and βH cysteine), 3.6-3.8 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.1-
4.4 (m, 4 H, αH lysine and αH cysteine). 
#2(691): K-(PEG24-FolA)-K-(Sph3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 2.1-2.4 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 3.0-3.6 (m, 128 
H, -CH2- Tp, εH lysine and βH cysteine), 3.6-3.8 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4.1-4.6 (m, 7H, αH lysine, αH cysteine, αH glutamic acid and -CH2-N- pteroic 
acid), 6.7-6.9 (d, 2H, aromatic ring H pteroic acid), 7.6-7.7 (d, 2H, aromatic ring H pteroic 
acid), 8.8 (s, 1H, aromatic ring H pteroic acid). 
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#3(692): K-(PEG24-Acetate)-K-(Sph4-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 1.98 (s, 3H, acetate 
CH3), 2.4-2.7 (m, 34 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 3.0-3.6 (m, 168 H, -CH2- 
Tp, εH lysine and βH cysteine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.1-
4.4 (m, 4 H, αH lysine and αH cysteine). 
#4(693): K-(PEG24-FolA)-K-(Sph4-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 2.0-2.4 (m, 4 H, βγH 
glutamic acid), 2.4-2.7 (m, 34 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.1 (m, 8 H, 
εH lysine and cysteine), 3.0-3.6 (m, 160 H, -CH2- Tp), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.1-4.6 (m, 7H, αH lysine, αH cysteine, αH glutamic acid and -CH2-N- 
pteroic acid), 6.7-6.9 (d, 2H, aromatic ring H pteroic acid), 7.6-7.7 (d, 2H, aromatic ring H 
pteroic acid), 8.8 (s, 1H, aromatic ring H pteroic acid). 
#5(788): K-(PEG24-E)-K-[(H-Stp)3-H-C]2 
1H-NMR spectrum in D2O. δ (ppm) =1.1-1.8 (m, 12 H, βγδH lysine), 1.8-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.6 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 120 
H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.1-4.7 (m, 13 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid), 
7.1-7.4 (m, 8 H, aromatic H histidine), 8.5 (m, 8 H, aromatic H histidine). 
#6(789): K-(PEG24-FolA)-K-[(H-Stp)3-H-C]2 
1H-NMR spectrum in D2O. δ (ppm) =1.1-1.7 (m, 12 H, βγδH lysine), 1.8-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 120 
H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 15 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.6-6.8 (d, 2H, aromatic ring H pteroic acid), 7.1-7.3 (m, 8 H, 
aromatic H histidine), 7.5-7.6 (d, 2H, aromatic ring H pteroic acid), 8.5-8.6 (m, 8 H, 
aromatic H histidine), 8.68 (s, 1H, aromatic ring H pteroic acid). 
#7(790): K-(PEG24-E)-K-[(H-Stp)4-H-C]2 
1H-NMR spectrum in D2O. δ (ppm) =1.1-1.7 (m, 12 H, βγδH lysine), 1.8-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.6 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 156 
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H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.5-3.6 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 15 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid), 
7.1-7.3 (m, 8 H, aromatic H histidine), 8.5-8.7 (m, 8 H, aromatic H histidine). 
#8(791): K-(PEG24-FolA)-K-[(H-Stp)4-H-C]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.1-1.7 (m, 12 H, βγδH lysine), 1.8-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.6 (m, 34 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 128 
H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 17 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.6-6.8 (d, 2H, aromatic ring H pteroic acid), 7.1-7.4 (m, 10 H, 
aromatic H histidine), 7.5-7.7 (d, 2H, aromatic ring H pteroic acid), 8.4-8.6 (m, 10 H, 
aromatic H histidine), 8.7 (s, 1H, aromatic ring H pteroic acid). 
#9(879): K-(PEG24-E)-K-(Stp3-Y3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 2.1-2.4 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.7-3.5 (m, 96 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 11 H, αH lysine, αH cysteine, αH glutamic acid, αH tyrosine), 
6.7-7.2 (m, 24 H, aromatic ring tyrosine). 
#10(880): K-(PEG24-FolA)-K-(Stp3-Y3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 2.1-2.4 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.7-3.5 (m, 116 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 13 H, αH lysine, αH cysteine, αH tyrosine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.6-7.2 (m, 26 H, aromatic ring H tyrosine, aromatic ring H 
pteroic acid), 7.6-7.7 (d, 2H, aromatic ring H pteroic acid), 8.79 (s, 1H, aromatic ring H 
pteroic acid). 
#11(881): K-(PEG24-E)-K-(Stp4-Y3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 2.1-2.4 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 34 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.7-3.5 (m, 148 
H, -CH2- Tp), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.7 (m, 11 H, αH 
lysine, αH cysteine, αH glutamic acid, αH tyrosine), 6.6-7.1 (m, 24 H, aromatic ring 
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tyrosine). 
#12(882): K-(PEG24-FolA)-K-(Stp4-Y3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 2.1-2.4 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 34 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.7-3.5 (m, 148 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 13 H, αH lysine, αH cysteine, αH tyrosine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.7-7.2 (m, 26 H, aromatic ring H tyrosine, aromatic ring H 
pteroic acid), 7.6-7.7 (d, 2H, aromatic ring H pteroic acid), 8.7 (s, 1H, aromatic ring H 
pteroic acid). 
#13(714): K-(PEG24-E)-K-(Sph3-Y3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 1.9-2.3 (m, 4 H, βγH 
glutamic acid), 2.5-2.6 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.7-3.6 (m, 140 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.6 (m, 11 H, αH lysine, αH cysteine, αH glutamic acid, αH tyrosine), 
6.7-7.2 (m, 24 H, aromatic ring tyrosine). 
#14(715): K-(PEG24-FolA)-K-(Sph3-Y3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.7-3.6 (m, 140 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 13 H, αH lysine, αH cysteine, αH tyrosine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.7-7.2 (m, 26 H, aromatic ring H tyrosine, aromatic ring H 
pteroic acid), 7.6-7.8 (d, 2H, aromatic ring H pteroic acid), 8.8 (s, 1H, aromatic ring H 
pteroic acid). 
#15(716): K-(PEG24-E)-K-(Sph4-Y3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.5-2.7 (m, 34 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.7-3.6 (m, 160 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.5 (m, 11 H, αH lysine, αH cysteine, αH glutamic acid, αH tyrosine), 
6.7-7.2 (m, 24 H, aromatic ring tyrosine). 
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#16(717): K-(PEG24-FolA)-K-(Sph4-Y3-C)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 2.1-2.4 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 34 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.7-3.6 (m, 160 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 13 H, αH lysine, αH cysteine, αH tyrosine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.6-7.2 (m, 26 H, aromatic ring H tyrosine, aromatic ring H 
pteroic acid), 7.6-7.7 (d, 2H, aromatic ring H pteroic acid), 8.79 (s, 1H, aromatic ring H 
pteroic acid). 
#17(792): K-(PEG24-E)-K-[(H-Stp)3-H-Y3-C]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.1-1.7 (m, 12 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 132 
H, -CH2- Tp, εH lysine, βH cysteine, βH tyrosine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-
O- dPEG24, -CH2-N- dPEG24), 4.0-4.7 (m, 19 H, αH lysine, αH cysteine, αH tyrosine, αH 
glutamic acid, αH histidine), 6.5-7.3 (m, 32 H, aromatic H tyrosine, aromatic H histidine), 
8.4-8.6 (m, 8 H, aromatic H histidine). 
#18(793): K-(PEG24-FolA)-K-[(H-Stp)3-H-Y3-C]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.1-1.5 (m, 12 H, βγδH lysine), 1.9-2.1 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 132 
H, -CH2- Tp, εH lysine, βH cysteine, βH tyrosine and βH histidine), 3.5-3.6 (m, 98 H, -CH2-
O- dPEG24, -CH2-N- dPEG24), 4.0-4.7 (m, 21 H, αH lysine, αH cysteine, αH tyrosine, αH 
glutamic acid, αH histidine and -CH2-N- pteroic acid), 6.5-7.3 (m, 34 H, aromatic H tyrosine, 
aromatic ring H pteroic acid, aromatic H histidine), 7.2-7.4 (m, 8 H,), 7.5-7.6 (d, 2H, 
aromatic ring H pteroic acid), 8.4-8.6 (m, 8 H, aromatic H histidine), 8.69 (s, 1H, aromatic 
ring H pteroic acid). 
#19(794): K-(PEG24-E)-K-[(H-Stp)4-H-Y3-C]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.1-1.5 (m, 12 H, βγδH lysine), 1.8-2.1 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 26 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 168 
H, -CH2- Tp, εH lysine, βH cysteine, βH tyrosine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-
O- dPEG24, -CH2-N- dPEG24), 4.0-4.7 (m, 21 H, αH lysine, αH cysteine, αH tyrosine, αH 
glutamic acid, αH histidine), 6.5-7.3 (m, 34 H, aromatic H tyrosine, aromatic H histidine), 
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8.4-8.6 (m, 10 H, aromatic H histidine). 
#20(795): K-(PEG24-FolA)-K-[(H-Stp)4-H-Y3-C]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 12 H, βγδH lysine), 1.8-2.1 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 34 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 168 
H, -CH2- Tp, εH lysine, βH cysteine, βH tyrosine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-
O- dPEG24, -CH2-N- dPEG24), 4.0-4.7 (m, 23 H, αH lysine, αH cysteine, αH tyrosine, αH 
glutamic acid, αH histidine and -CH2-N- pteroic acid), 6.5-7.3 (m, 34 H, aromatic ring H 
tyrosine, aromatic ring H pteroic acid and aromatic H histidine), 7.5-7.6 (d, 2H, aromatic 
ring H pteroic acid), 8.4-8.6 (m, 10 H, aromatic H histidine), 8.69 (s, 1H, aromatic ring H 
pteroic acid). 
#21(732): K-(PEG24-E)-K-[K-(Stp3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 208 
H, -CH2- Tp, εH lysine and βH cysteine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4.0-4.6 (m, 9 H, αH lysine, αH cysteine, αH glutamic acid). 
#22(733): K-(PEG24-FolA)-K-[K-(Stp3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 208 
H, -CH2- Tp, εH lysine and βH cysteine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4.0-4.6 (m, 11H, αH lysine, αH cysteine, αH glutamic acid and -CH2-N- pteroic 
acid), 6.7-6.8 (d, 2H, aromatic ring H pteroic acid), 7.5-7.7 (d, 2H, aromatic ring H pteroic 
acid), 8.75 (s, 1H, aromatic ring H pteroic acid). 
#23(734): K-(PEG24-E)-K-[K-(Stp4-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 272 
H, -CH2- Tp, εH lysine and βH cysteine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4.0-4.6 (m, 9 H, αH lysine, αH cysteine, αH glutamic acid). 
#24(735): K-(PEG24-FolA)-K-[K-(Stp4-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
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glutamic acid), 2.4-2.6 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 272 
H, -CH2- Tp, εH lysine and βH cysteine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24),  4.0-4.7 (m, 11H, αH lysine, αH cysteine, αH glutamic acid and -CH2-N- pteroic 
acid), 6.7-6.8 (d, 2H, aromatic ring H pteroic acid), 7.5-7.7 (d, 2H, aromatic ring H pteroic 
acid), 8.75 (s, 1H, aromatic ring H pteroic acid). 
#25(706): K-(PEG24-A)-K-[K-(Sph3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 27 H, βH alanine, βγδH lysine), 2.4-2.6 
(m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 3.0-3.6 (m, 256 H, -CH2- Tp, εH lysine 
and βH cysteine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.4 (m, 9 H, 
αH lysine, αH cysteine, αH alanine). 
#26(707): K-(PEG24-FolA)-K-[K-(Sph3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 3.0-3.5 (m, 256 
H, -CH2- Tp, εH lysine and βH cysteine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4.0-4.6 (m, 11H, αH lysine, αH cysteine, αH glutamic acid and -CH2-N- pteroic 
acid), 6.8-6.9 (d, 2H, aromatic ring H pteroic acid), 7.6-7.7 (d, 2H, aromatic ring H pteroic 
acid), 8.82 (s, 1H, aromatic ring H pteroic acid). 
#27(708): K-(PEG24-A)-K-[K-(Sph4-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 27 H, βH alanine, βγδH lysine), 2.4-2.7 
(m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 3.0-3.6 (m, 336 H, -CH2- Tp, εH lysine 
and βH cysteine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.7 (m, 9 H, 
αH lysine, αH cysteine, αH alanine). 
#28(709): K-(PEG24-FolA)-K-[K-(Sph4-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.7 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 3.0-3.5 (m, 336 
H, -CH2- Tp, εH lysine and βH cysteine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4.0-4.6 (m, 11H, αH lysine, αH cysteine, αH glutamic acid and -CH2-N- pteroic 
acid), 6.7-6.9 (d, 2H, aromatic ring H pteroic acid), 7.6-7.7 (d, 2H, aromatic ring H pteroic 
acid), 8.81 (s, 1H, aromatic ring H pteroic acid). 
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#29(761): K-(PEG24-E)-K-[H-K-((H-Stp)3-H-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.7 (m, 24 H, βγδH lysine), 1.8-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 244 
H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 27 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid), 
7.1-7.3 (m, 18 H, aromatic H histidine), 8.5-8.6 (m, 18 H, aromatic H histidine). 
#30(762): K-(PEG24-FolA)-K-[H-K-((H-Stp)3-H-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.7 (m, 24 H, βγδH lysine), 1.8-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 244 
H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 29 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.6-6.8 (d, 2H, aromatic ring H pteroic acid), 7.1-7.3 (m, 18 H, 
aromatic H histidine), 7.5-7.6 (d, 2H, aromatic ring H pteroic acid), 8.4-8.6 (m, 18 H, 
aromatic H histidine), 8.69 (s, 1H, aromatic ring H pteroic acid). 
#31(763): K-(PEG24-E)-K-[H-K-((H-Stp)4-H-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.7 (m, 24 H, βγδH lysine), 1.8-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.6 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.5 (m, 256 
H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 31 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid), 
7.1-7.3 (m, 22 H, aromatic H histidine), 8.4-8.6 (m, 22 H, aromatic H histidine). 
#32(764): K-(PEG24-FolA)-K-[H-K-((H-Stp)4-H-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.7 (m, 24 H, βγδH lysine), 1.8-2.2 (m, 4 H, βγH 
glutamic acid), 2.3-2.6 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.8-3.5 (m, 316 
H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 33 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.6-6.8 (d, 2H, aromatic ring H pteroic acid), 7.1-7.3 (m, 22 H, 
aromatic H histidine), 7.5-7.6 (d, 2H, aromatic ring H pteroic acid), 8.4-8.6 (m, 22 H, 
aromatic H histidine), 8.69 (s, 1H, aromatic ring H pteroic acid). 
#33(712): K-(PEG24-E)-K-[H-K-((H-Sph)3-H-C)2]2 
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1H-NMR spectrum in D2O. δ (ppm) = 1.1-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.8-3.6 (m, 292 
H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 3.9-4.7 (m, 27 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid), 
7.2-7.4 (m, 18 H, aromatic H histidine), 8.5-8.7 (m, 18 H, aromatic H histidine). 
#34(713): K-(PEG24-FolA)-K-[H-K-((H-Sph)3-H-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.1-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.9-3.6 (m, 292 
H, -CH2- Tp, εH lysine, βH cysteine and βH histidine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.1-4.7 (m, 29 H, αH lysine, αH cysteine, αH histidine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.7-6.9 (d, 2H, aromatic ring H pteroic acid), 7.2-7.4 (m, 18 H, 
aromatic H histidine), 7.6-7.7 (d, 2H, aromatic ring H pteroic acid), 8.5-8.7 (m, 18 H, 
aromatic H histidine), 8.78 (s, 1H, aromatic ring H pteroic acid). 
#35(875): K-(PEG24-E)-K-[K-(Stp3-Y3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 232 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.5 (m, 21 H, αH lysine, αH cysteine, αH glutamic acid, αH tyrosine), 
6.6-7.1 (m, 48 H, aromatic ring tyrosine). 
#36(876): K-(PEG24-FolA)-K-[K-(Stp3-Y3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 232 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.6 (m, 23 H, αH lysine, αH cysteine, αH tyrosine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.6-7.2 (m, 50 H, aromatic ring H tyrosine, aromatic ring H 
pteroic acid), 7.5-7.7 (d, 2H, aromatic ring H pteroic acid), 8.71 (s, 1H, aromatic ring H 
pteroic acid). 
#37(877): K-(PEG24-E)-K-[K-(Stp4-Y3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 296 
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H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.6 (m, 21 H, αH lysine, αH cysteine, αH glutamic acid, αH tyrosine), 
6.6-7.1 (m, 48 H, aromatic ring tyrosine). 
#38(878): K-(PEG24-FolA)-K-[K-(Stp4-Y3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 296 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.6 (m, 23 H, αH lysine, αH cysteine, αH tyrosine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.6-7.2 (m, 50 H, aromatic ring H tyrosine, aromatic ring H 
pteroic acid), 7.5-7.7 (d, 2H, aromatic ring H pteroic acid), 8.71 (s, 1H, aromatic ring H 
pteroic acid). 
#39(765): K-(PEG24-E)-K-[H-K-((H-Stp)3-H-Y3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.8-2.1 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 268 
H, -CH2- Tp, εH lysine, βH cysteine, βH tyrosine, βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- 
dPEG24, -CH2-N- dPEG24), 3.9-4.7 (m, 39 H, αH lysine, αH cysteine, αH tyrosine, αH 
glutamic acid, αH histidine), 6.5-7.1 (m, 48 H, aromatic ring tyrosine), 7.1-7.3 (m, 18 H, 
aromatic H histidine), 8.4-8.6 (m, 18 H, aromatic H histidine). 
#40(766): K-(PEG24-FolA)-K-[H-K-((H-Stp)3-H-Y3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.8-2.1 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 50 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 268 
H, -CH2- Tp, εH lysine, βH cysteine, βH tyrosine, βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- 
dPEG24, -CH2-N- dPEG24), 3.9-4.7 (m, 41 H, αH lysine, αH cysteine, αH tyrosine, αH 
glutamic acid, αH histidine and -CH2-N- pteroic acid), 6.5-7.1 (m, 50 H, aromatic ring H 
tyrosine, aromatic ring H pteroic acid), 7.1-7.3 (m, 18 H, aromatic H histidine), 7.5-7.6 (d, 
2H, aromatic ring H pteroic acid), 8.4-8.6 (m, 18 H, aromatic H histidine), 8.64 (s, 1H, 
aromatic ring H pteroic acid). 
#41(767): K-(PEG24-E)-K-[H-K-((H-Stp)4-H-Y3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.8-2.1 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 340 
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H, -CH2- Tp, εH lysine, βH cysteine, βH tyrosine, βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- 
dPEG24, -CH2-N- dPEG24), 3.9-4.7 (m, 43 H, αH lysine, αH cysteine, αH tyrosine, αH 
glutamic acid, αH histidine), 6.5-7.1 (m, 48 H, aromatic ring tyrosine), 7.1-7.3 (m, 22 H, 
aromatic H histidine), 8.4-8.6 (m, 22 H, aromatic H histidine). 
#42(768): K-(PEG24-FolA)-K-[H-K-((H-Stp)3-H-Y3-C)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.0-1.5 (m, 24 H, βγδH lysine), 1.8-2.1 (m, 4 H, βγH 
glutamic acid), 2.3-2.5 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.6-3.5 (m, 340 
H, -CH2- Tp, εH lysine, βH cysteine, βH tyrosine, βH histidine), 3.5-3.7 (m, 98 H, -CH2-O- 
dPEG24, -CH2-N- dPEG24), 3.9-4.7 (m, 45 H, αH lysine, αH cysteine, αH tyrosine, αH 
glutamic acid, αH histidine and -CH2-N- pteroic acid), 6.5-7.1 (m, 50 H, aromatic ring H 
tyrosine, aromatic ring H pteroic acid), 7.1-7.3 (m, 22 H, aromatic H histidine), 7.5-7.6 (d, 
2H, aromatic ring H pteroic acid), 8.4-8.6 (m, 22 H, aromatic H histidine), 8.69 (s, 1H, 
aromatic ring H pteroic acid). 
769: TNB-C-Stp3-K-(Stp3-C-TNB)2 
1H-NMR spectrum in D2O.δ (ppm) = 1.1-1.4 (m, 6H, βγδH lysine), 2.3-2.7 (m, 36 H, -CO-
CH2-CH2-CO- succinic acid), 2.9-3.8 (m, 152 H, -CH2- tepa, βH cysteine, εH lysine), 4.1-
4.7 (m, 4 H, αH cysteine, lysine), 7.5-7.8 (m, 6 H, aromatic H TNB), 7.9-8.1(m, 3 H, 
aromatic H TNB) 
770: TNB-C-H-(Stp-H)3-K-(H-Stp)3-H-C-TNB)2 
1H-NMR spectrum in D2O.δ (ppm) = 1.1-1.4 (m, 6H, βγδH lysine), 2.3-2.7 (m, 36 H, -CO-
CH2-CH2-CO- succinic acid), 2.9-3.8 (m, 176 H, -CH2- tepa, βH cysteine, βH histidine, εH 
lysine), 4.1-4.7 (m, 16 H, αH cysteine, lysine, histidine), 7.2-7.4 (m, 12 H, aromatic H 
histidine), 7.5-7.8 (m, 6 H, aromatic H TNB), 7.9-8.1(m, 3 H, aromatic H TNB), 8.5-8.7 (m, 
12 H, aromatic H histidine). 
873: K-(PEG24-FolA)-K-[K-(Sph4-C-TNB)2]2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 24 H, βγδH lysine), 1.9-2.2 (m, 4 H, βγH 
glutamic acid), 2.4-2.7 (m, 66 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 3.0-3.5 (m, 336 
H, -CH2- Tp, εH lysine and βH cysteine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4.0-4.6 (m, 11H, αH lysine, αH cysteine, αH glutamic acid and -CH2-N- pteroic 
acid), 6.7-6.9 (d, 2H, aromatic ring H pteroic acid), 7.5-8.1 (m, 14H, aromatic ring H pteroic 
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acid, aromatic H TNB), 8.81 (s, 1H, aromatic ring H pteroic acid). 
874: K-(PEG24-FolA)-K-(Sph4-Y3-C-TNB)2 
1H-NMR spectrum in D2O. δ (ppm) = 1.2-1.6 (m, 12 H, βγδH lysine), 2.1-2.4 (m, 4 H, βγH 
glutamic acid), 2.4-2.6 (m, 34 H, -CO-CH2-CH2-CO-, -CO-CH2- dPEG24), 2.7-3.6 (m, 160 
H, -CH2- Tp, εH lysine, βH cysteine and βH tyrosine), 3.6-3.7 (m, 98 H, -CH2-O- dPEG24, 
-CH2-N- dPEG24), 4.0-4.7 (m, 13 H, αH lysine, αH cysteine, αH tyrosine, αH glutamic acid 
and -CH2-N- pteroic acid), 6.6-7.2 (m, 26 H, aromatic ring H tyrosine, aromatic ring H 
pteroic acid), 7.5-8.1 (m, 8H, aromatic ring H pteroic acid, aromatic H TNB), 8.79 (s, 1H, 
aromatic ring H pteroic acid). 
905: K-(K-OA2)-Stp4-C 
1H-NMR spectrum in D2O. δ(ppm)= 0.7-0.8 (m, 6 H, -CH3 oleic acid), 1.2-2.2 (m, 68 H, -
CH2 oleic acid, βγδH lysine, αH oleic acid), 2.4-2.6 (m, 16 H, -CO-CH2-CH2-CO- succinic 
acid), 2.9-3.1 (m, 6 H, εH lysine, βH cysteine), 3.2-3.5 (m, 64 H, -CH2- TEPA), 4.1-4.2 (m, 
3 H, αH lysine, αH cysteine), 5.0-5.3 (m, 4 H, =CH- oleic acid). 
906: K-(K-OA2)-K-(Stp2-C)2  
1H-NMR spectrum in D2O. δ(ppm)= 0.7-0.8 (m, 6 H, -CH3 oleic acid), 1.2-2.2 (m, 74 H, -
CH2 oleic acid, βγδH lysine, αH oleic acid), 2.4-2.6 (m, 16 H, -CO-CH2-CH2-CO- succinic 
acid), 2.9-3.1 (m, 10 H, εH lysine, βH cysteine), 3.2-3.5 (m, 64 H, -CH2- TEPA), 4.1-4.2 
(m, 5 H, αH lysine, αH cysteine), 5.0-5.3 (m, 4 H, =CH- oleic acid). 
907: K-(K-OA2)-K-(Stp3-C)2  
1H-NMR spectrum in D2O. δ(ppm)= 0.7-0.8 (m, 6 H, -CH3 oleic acid), 1.2-2.2 (m, 74 H, - 
CH2 oleic acid, βγδH lysine, αH oleic acid), 2.4-2.6 (m, 24 H, -CO-CH2-CH2-CO- succinic 
acid), 2.9-3.1 (m, 10 H, εH lysine, βH cysteine), 3.2-3.5 (m, 96 H, -CH2- TEPA), 4.1-4.2 
(m, 5 H, αH lysine, αH cysteine), 5.0-5.3 (m, 4 H, =CH- oleic acid). 
908: K-(K-OA2)-K-(Stp4-C)2 
1H-NMR spectrum in D2O. δ(ppm)= 0.7-0.8 (m, 6 H, -CH3 oleic acid), 1.2-2.2 (m, 74 H, -
CH2 oleic acid, βγδH lysine, αH oleic acid), 2.4-2.6 (m, 32 H, -CO-CH2-CH2-CO- succinic 
acid), 2.9-3.1 (m, 10 H, εH lysine, βH cysteine), 3.2-3.5 (m, 128 H, -CH2- TEPA), 4.1-4.2 
(m, 5 H, αH lysine, αH cysteine), 5.0-5.3 (m, 4 H, =CH- oleic acid). 
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909: K-(K-OA2)-K-[K-(Stp-C)2]2 
1H-NMR spectrum in D2O. δ(ppm)= 0.7-0.8 (m, 6 H, -CH3 oleic acid), 1.2-2.2 (m, 86 H, -
CH2 oleic acid, βγδH lysine, αH oleic acid), 2.4-2.6 (m, 16 H, -CO-CH2-CH2-CO- succinic 
acid), 2.9-3.1 (m, 18 H, εH lysine, βH cysteine), 3.2-3.5 (m, 64 H, -CH2- TEPA), 4.1-4.2 
(m, 9 H, αH lysine, αH cysteine), 5.0-5.3 (m, 4 H, =CH- oleic acid). 
910: K-(K-OA2)-K-[K-(Stp2-C)2]2 
1H-NMR spectrum in D2O. δ(ppm)= 0.7-0.8 (m, 6 H, -CH3 oleic acid), 1.2-2.2 (m, 86 H, -
CH2 oleic acid, βγδH lysine, αH oleic acid), 2.4-2.6 (m, 32 H, -CO-CH2-CH2-CO- succinic 
acid), 2.9-3.1 (m, 18 H, εH lysine, βH cysteine), 3.2-3.5 (m, 128 H, -CH2- TEPA), 4.1-4.2 
(m, 9 H, αH lysine, αH cysteine), 5.0-5.3 (m, 4 H, =CH- oleic acid). 
911: K-(K-OA2)-K-{K[K-(Stp-C)2]2}2 
1H-NMR spectrum in D2O. δ(ppm)= 0.7-0.8 (m, 6 H, -CH3 oleic acid), 1.2-2.2 (m, 110 H, -
CH2 oleic acid, βγδH lysine, αH oleic acid), 2.4-2.6 (m, 32 H, -CO-CH2-CH2-CO- succinic 
acid), 2.9-3.1 (m, 34 H, εH lysine, βH cysteine), 3.2-3.5 (m, 128 H, -CH2- TEPA), 4.1-4.2 
(m, 17 H, αH lysine, αH cysteine), 5.0-5.3 (m, 4 H, =CH- oleic acid). 
728: K-(PEG24-E)-K-(Stp4-C-K-OA2)2 
1H-NMR spectrum in D2O. δ (ppm) = 0.76 (m, 12 H, -CH3 oleic acid), 1.0-2.25 (m, 136 H, 
βγδH lysine, βH glutamic acid, -CH2- oleic acid), 2.4-2.6 (m, 34 H, -CO-CH2-CH2-CO- 
Tepa, -CO-CH2- dPEG24), 2.8-3.1 (m, 14 H, εH lysine, βH cysteine, γH glutamic acid), 3.1-
3.5 (m, 128 H, -CH2- Tepa), 3.5-3.6 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.5 
(m, 7 H, αH lysine, αH cysteine, αH glutamic acid), 4.9-5.3 (m, 8 H, =CH- oleic acid). 
729: K-(PEG24-FolA)-K-(Stp4-C-K-OA2)2 
1H-NMR spectrum in D2O. δ (ppm) = 0.71 (m, 12 H, -CH3 oleic acid), 0.8-2.3 (m, 136 H, 
βγδH lysine, βH glutamic acid, -CH2- oleic acid), 2.4-2.6 (m, 34 H, -CO-CH2-CH2-CO- 
Tepa, -CO-CH2- dPEG24), 2.6-3.1 (m, 14 H, εH lysine, βH cysteine, γH glutamic acid), 3.1-
3.5 (m, 128 H, -CH2- Tepa), 3.5-3.6 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.7 
(m, 9 H, αH lysine, αH cysteine, αH glutamic acid, -CH2-N- pteroic acid), 4.8-5.3 (m, 8 H, 
=CH- oleic acid), 6.7 (d,2H, aromatic ring H pteroic acid), 7.6 (d, 2H, aromatic ring H 
pteroic acid), 8.7 (s, 1H, aromatic ring H pteroic acid). 
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730:K-(PEG24-E)-K-(K-OA2)-K-(Stp4-C)2 
1H-NMR spectrum in D2O. δ(ppm)= 0.7-0.8 (m, 6 H, -CH3 oleic acid), 1.2-2.2 (m, 82 H, - 
CH2 oleic acid, βγδH lysine, βH glutamic acid, αH oleic acid), 2.4-2.6 (m, 34 H, -CO-CH2-
CH2-CO- Tepa, -CO-CH2- dPEG24), 2.8-3.1 (m, 14 H, εH lysine, βH cysteine, γH glutamic 
acid), 3.1-3.5 (m, 128 H, -CH2- Tepa), 3.5-3.6 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4,1-4,2 (m, 7 H, αH lysine, αH cysteine, αH glutamic acid), 5.0-5.4 (m, 4 H, =CH- 
oleic acid). 
731: K-(PEG24-FolA)-K-(K-OA2)-K-(Stp4-C)2 
1H-NMR spectrum in D2O. δ(ppm)= 0.7-0.8 (m, 6 H, -CH3 oleic acid), 1.2-2.2 (m, 82 H, -
CH2 oleic acid, βγδH lysine, βH glutamic acid, αH oleic acid), 2.4-2.6 (m, 34 H, -CO-CH2-
CH2-CO- Tepa, -CO-CH2- dPEG24), 2.7-3.1 (m, 14 H, εH lysine, βH cysteine, γH glutamic 
acid), 3.1-3.5 (m, 128 H, -CH2- Tepa), 3.5-3.6 (m, 98 H, -CH2-O- dPEG24, -CH2-N- 
dPEG24), 4.0-4.7 (m, 9 H, αH lysine, αH cysteine, αH glutamic acid, -CH2-N- pteroic acid), 
5.0-5.4 (m, 4 H, =CH- oleic acid), 6.7 (d, 2H, aromatic ring H pteroic acid), 7.6 (d, 2H, 
aromatic ring H pteroic acid), 8.7 (s, 1H, aromatic ring H pteroic acid). 
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